EP2331731A2 - Aqueous electrophoretic deposition - Google Patents
Aqueous electrophoretic depositionInfo
- Publication number
- EP2331731A2 EP2331731A2 EP09736877A EP09736877A EP2331731A2 EP 2331731 A2 EP2331731 A2 EP 2331731A2 EP 09736877 A EP09736877 A EP 09736877A EP 09736877 A EP09736877 A EP 09736877A EP 2331731 A2 EP2331731 A2 EP 2331731A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- peak
- use according
- charged
- unbalanced
- signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000001652 electrophoretic deposition Methods 0.000 title claims abstract description 136
- 238000000576 coating method Methods 0.000 claims abstract description 53
- 239000000758 substrate Substances 0.000 claims abstract description 41
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims description 112
- 239000000725 suspension Substances 0.000 claims description 67
- -1 polytetrafluoroethylene Polymers 0.000 claims description 59
- 239000012736 aqueous medium Substances 0.000 claims description 49
- 230000005684 electric field Effects 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 26
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 238000004070 electrodeposition Methods 0.000 claims description 21
- 239000000839 emulsion Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 229920006318 anionic polymer Polymers 0.000 claims description 8
- 230000007547 defect Effects 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 239000007943 implant Substances 0.000 claims description 8
- 229920002521 macromolecule Polymers 0.000 claims description 8
- 210000003463 organelle Anatomy 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 210000003850 cellular structure Anatomy 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 125000000129 anionic group Chemical group 0.000 claims description 6
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 125000002091 cationic group Chemical group 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 239000012867 bioactive agent Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000004053 dental implant Substances 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 150000002739 metals Chemical class 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 229920001222 biopolymer Polymers 0.000 claims description 3
- 229920006317 cationic polymer Polymers 0.000 claims description 3
- 239000003973 paint Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 241000206575 Chondrus crispus Species 0.000 claims description 2
- 241000195493 Cryptophyta Species 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229910045601 alloy Inorganic materials 0.000 claims description 2
- 239000000956 alloy Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 238000001029 thermal curing Methods 0.000 claims description 2
- 229920001169 thermoplastic Polymers 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 150000001793 charged compounds Chemical class 0.000 claims 1
- 239000002070 nanowire Substances 0.000 claims 1
- 229920001083 polybutene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 1
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000012224 working solution Substances 0.000 claims 1
- 238000000151 deposition Methods 0.000 abstract description 88
- 230000008021 deposition Effects 0.000 abstract description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 54
- 239000002904 solvent Substances 0.000 abstract description 28
- 238000005868 electrolysis reaction Methods 0.000 abstract description 17
- 239000007900 aqueous suspension Substances 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract description 6
- 238000000354 decomposition reaction Methods 0.000 abstract description 5
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 229910052763 palladium Inorganic materials 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 239000003125 aqueous solvent Substances 0.000 abstract description 2
- 239000007772 electrode material Substances 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract description 2
- 238000013459 approach Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 62
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 23
- 239000000843 powder Substances 0.000 description 22
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 229910017604 nitric acid Inorganic materials 0.000 description 11
- 239000007789 gas Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 229910052593 corundum Inorganic materials 0.000 description 9
- 229910001845 yogo sapphire Inorganic materials 0.000 description 9
- 239000000919 ceramic Substances 0.000 description 8
- 230000016507 interphase Effects 0.000 description 8
- 150000002632 lipids Chemical group 0.000 description 8
- 235000019260 propionic acid Nutrition 0.000 description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 235000010215 titanium dioxide Nutrition 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229920001940 conductive polymer Polymers 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 150000003431 steroids Chemical group 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000010439 graphite Substances 0.000 description 5
- 229910002804 graphite Inorganic materials 0.000 description 5
- 229960004130 itraconazole Drugs 0.000 description 5
- 239000004922 lacquer Substances 0.000 description 5
- 229920005610 lignin Chemical group 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229920006324 polyoxymethylene Polymers 0.000 description 5
- 230000003746 surface roughness Effects 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- QYEXBYZXHDUPRC-UHFFFAOYSA-N B#[Ti]#B Chemical compound B#[Ti]#B QYEXBYZXHDUPRC-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 229910033181 TiB2 Inorganic materials 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 125000002843 carboxylic acid group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000005305 interferometry Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 150000002960 penicillins Chemical class 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000007088 Archimedes method Methods 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 229940022663 acetate Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004411 aluminium Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 3
- 238000009694 cold isostatic pressing Methods 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000021309 simple sugar Nutrition 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000935974 Paralichthys dentatus Species 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000000228 antimanic agent Substances 0.000 description 2
- 229910052787 antimony Inorganic materials 0.000 description 2
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 229960001671 azapropazone Drugs 0.000 description 2
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- ZRIHAIZYIMGOAB-UHFFFAOYSA-N butabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960004782 chlordiazepoxide Drugs 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960004362 clorazepate Drugs 0.000 description 2
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 2
- JMFRWRFFLBVWSI-NSCUHMNNSA-N coniferol Chemical compound COC1=CC(\C=C\CO)=CC=C1O JMFRWRFFLBVWSI-NSCUHMNNSA-N 0.000 description 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001739 density measurement Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- PWHROYKAGRUWDQ-UHFFFAOYSA-N difenpiramide Chemical compound C=1C=CC=NC=1NC(=O)CC(C=C1)=CC=C1C1=CC=CC=C1 PWHROYKAGRUWDQ-UHFFFAOYSA-N 0.000 description 2
- 229960001536 difenpiramide Drugs 0.000 description 2
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 2
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 2
- 229960000394 droperidol Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005370 electroosmosis Methods 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000011133 lead Substances 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 229940013798 meclofenamate Drugs 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-M meclofenamic acid(1-) Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-M 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229960001703 methylphenobarbital Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000006070 nanosuspension Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- 229960001652 norethindrone acetate Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 238000010951 particle size reduction Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002895 phenylbutazone Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920000767 polyaniline Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 238000003918 potentiometric titration Methods 0.000 description 2
- 229960002847 prasterone Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- 239000011135 tin Substances 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- LZFOPEXOUVTGJS-ONEGZZNKSA-N trans-sinapyl alcohol Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O LZFOPEXOUVTGJS-ONEGZZNKSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- USFMMZYROHDWPJ-UHFFFAOYSA-N trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium Chemical compound CC(=C)C(=O)OCC[N+](C)(C)C USFMMZYROHDWPJ-UHFFFAOYSA-N 0.000 description 2
- UZNHKBFIBYXPDV-UHFFFAOYSA-N trimethyl-[3-(2-methylprop-2-enoylamino)propyl]azanium;chloride Chemical compound [Cl-].CC(=C)C(=O)NCCC[N+](C)(C)C UZNHKBFIBYXPDV-UHFFFAOYSA-N 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- ZERWDZDNDJBYKA-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O ZERWDZDNDJBYKA-UHFFFAOYSA-N 0.000 description 1
- RWBRUCCWZPSBFC-RXRZZTMXSA-N (20S)-20-hydroxypregn-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](O)C)[C@@]1(C)CC2 RWBRUCCWZPSBFC-RXRZZTMXSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- SEVKYLYIYIKRSW-DDWIOCJRSA-N (2r)-1-phenylpropan-2-amine;hydrochloride Chemical compound Cl.C[C@@H](N)CC1=CC=CC=C1 SEVKYLYIYIKRSW-DDWIOCJRSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- REHJTMDOJHAPJV-IVTQUDKZSA-N (6s,8r,9s,10r,13s,14s,17s)-17-hydroxy-6,10,13-trimethyl-17-prop-1-ynyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;hydrate Chemical compound O.C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 REHJTMDOJHAPJV-IVTQUDKZSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- QBWLKDFBINPHFT-UHFFFAOYSA-L 1,3,2$l^{2}-benzodioxabismin-4-one;hydrate Chemical compound O.C1=CC=C2C(=O)O[Bi]OC2=C1 QBWLKDFBINPHFT-UHFFFAOYSA-L 0.000 description 1
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VTHUYJIXSMGYOQ-KOORYGTMSA-N 17-hydroxyprogesterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 VTHUYJIXSMGYOQ-KOORYGTMSA-N 0.000 description 1
- 229930182834 17alpha-Estradiol Natural products 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- NZGKYNGOBSDZNY-YNFNDHOQSA-N 17beta-Hydroxyestr-4-en-3-one benzoate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)C1=CC=CC=C1 NZGKYNGOBSDZNY-YNFNDHOQSA-N 0.000 description 1
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- KDPQTPZDVJHMET-UHFFFAOYSA-N 3-acetoxy-1,3,5(10)-estratrien-17-one Natural products C1CC2(C)C(=O)CCC2C2CCC3=CC(OC(=O)C)=CC=C3C21 KDPQTPZDVJHMET-UHFFFAOYSA-N 0.000 description 1
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- ZVHNNCSUTNWKFC-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonyl)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperazine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZVHNNCSUTNWKFC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- BALGERHMIXFENA-UHFFFAOYSA-N 4-butylcyclohexane-1-carboxylic acid Chemical compound CCCCC1CCC(C(O)=O)CC1 BALGERHMIXFENA-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 229930190007 Baccatin Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- LRWSFOSWNAQHHW-UHFFFAOYSA-N Fluphenazine enanthate Chemical compound C1CN(CCOC(=O)CCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 LRWSFOSWNAQHHW-UHFFFAOYSA-N 0.000 description 1
- JKQQZJHNUVDHKP-FQJIPJFPSA-N Flurogestone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)C[C@@H]2O JKQQZJHNUVDHKP-FQJIPJFPSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GZHFODJQISUKAY-UHFFFAOYSA-N Methantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 GZHFODJQISUKAY-UHFFFAOYSA-N 0.000 description 1
- ROAIXOJGRFKICW-UHFFFAOYSA-N Methenamine hippurate Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- SIDLZWOQUZRBRU-UHFFFAOYSA-N Methyprylon Chemical compound CCC1(CC)C(=O)NCC(C)C1=O SIDLZWOQUZRBRU-UHFFFAOYSA-N 0.000 description 1
- NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 102400001357 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229920000557 Nafion® Polymers 0.000 description 1
- JKWKMORAXJQQSR-MOPIKTETSA-N Nandrolone Decanoate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC2 JKWKMORAXJQQSR-MOPIKTETSA-N 0.000 description 1
- TXLCJMHILCSZJG-QNTYDACNSA-N Nandrolone cyclohexanepropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCCC1 TXLCJMHILCSZJG-QNTYDACNSA-N 0.000 description 1
- ICNIVTHKZKRHPD-YNFNDHOQSA-N Nandrolone furylpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CO1 ICNIVTHKZKRHPD-YNFNDHOQSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- ZXSWTMLNIIZPET-ZOFHRBRSSA-N Normethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 ZXSWTMLNIIZPET-ZOFHRBRSSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940123317 Sulfonamide antibiotic Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- FDCINQSOYQUNKB-UHFFFAOYSA-N UNPD98205 Natural products C1CC2C3(C)CCC(OC(=O)C)CC3CCC2C2CCC(=O)C21C FDCINQSOYQUNKB-UHFFFAOYSA-N 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- KNDUBESZKGHTSA-CJVRWNGOSA-N [(3r,5s,8r,9s,10s,13s,14s)-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound O([C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(CC1)C)CC[C@]1([C@H]3CCC1=O)C)C(=O)C1=CC=CC=C1 KNDUBESZKGHTSA-CJVRWNGOSA-N 0.000 description 1
- SAOVUTZAPBDLOX-WSKGSGNSSA-N [(3r,5s,8r,9s,10s,13s,14s)-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] propanoate Chemical compound C1C[C@@H]2[C@@]3(C)CC[C@@H](OC(=O)CC)C[C@@H]3CC[C@H]2[C@@H]2CCC(=O)[C@]21C SAOVUTZAPBDLOX-WSKGSGNSSA-N 0.000 description 1
- QXKRUGDXPWHXHL-FQJIPJFPSA-N [(3s,8r,9s,10r,13s,14s,17s)-17-acetyloxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 QXKRUGDXPWHXHL-FQJIPJFPSA-N 0.000 description 1
- OQHMNEGOKQMOFM-BPSSIEEOSA-N [(3s,8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 OQHMNEGOKQMOFM-BPSSIEEOSA-N 0.000 description 1
- JVRUDYNTKOCRNP-ARZCWHKOSA-N [(3s,8r,9s,10r,13s,14s,17s)-3-acetyloxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] benzoate Chemical compound O([C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]3[C@@H]2CC1)OC(=O)C)C(=O)C1=CC=CC=C1 JVRUDYNTKOCRNP-ARZCWHKOSA-N 0.000 description 1
- BMDNPBLUVJZAEA-BPSSIEEOSA-N [(3s,8r,9s,10r,13s,14s,17s)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 BMDNPBLUVJZAEA-BPSSIEEOSA-N 0.000 description 1
- BGSWILYBWIQYKQ-DRKCKIEBSA-N [(3s,8r,9s,10r,13s,14s,17s)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] benzoate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CC[C@H](O)CC4=CC3)C)CC[C@@]21C)C(=O)C1=CC=CC=C1 BGSWILYBWIQYKQ-DRKCKIEBSA-N 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- AQMOXBCKEKPDRF-YNFNDHOQSA-N [(8r,9s,10r,13s,14s,17s)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] cyclohexanecarboxylate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)C1CCCCC1 AQMOXBCKEKPDRF-YNFNDHOQSA-N 0.000 description 1
- KDPQTPZDVJHMET-XSYGEPLQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)C)=CC=C3[C@H]21 KDPQTPZDVJHMET-XSYGEPLQSA-N 0.000 description 1
- VQHQLBARMFAKSV-AANPDWTMSA-N [(8r,9s,13s,14s,17s)-3-acetyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(OC(C)=O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 VQHQLBARMFAKSV-AANPDWTMSA-N 0.000 description 1
- YZNQMPPBWQTLFJ-TUFAYURCSA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CCC)(O)[C@@]1(C)C[C@@H]2O YZNQMPPBWQTLFJ-TUFAYURCSA-N 0.000 description 1
- MRECAIZOMKKXOZ-RPPPWEFESA-N [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(O)[C@@]1(C)C[C@@H]2O MRECAIZOMKKXOZ-RPPPWEFESA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- LTXUBHXFNYNXJW-NGOGOHBQSA-N acetic acid (8S,9S,10R,13S,14S,17S)-17-acetyl-16-(hydroxymethyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(CO)[C@H](C(=O)C)[C@@]1(C)CC2 LTXUBHXFNYNXJW-NGOGOHBQSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- NUKVZKPNSKJGBK-SPIKMXEPSA-N acetophenazine dimaleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 NUKVZKPNSKJGBK-SPIKMXEPSA-N 0.000 description 1
- 229960004035 acetophenazine maleate Drugs 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 229960000552 alclometasone Drugs 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960002692 allylestrenol Drugs 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 229950002552 anagestone acetate Drugs 0.000 description 1
- KDLNOQQQEBKBQM-DICPTYMLSA-N anagestone acetate Chemical compound C([C@@]12C)CCC=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 KDLNOQQQEBKBQM-DICPTYMLSA-N 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 229950009148 androstenediol Drugs 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000244 anti-pseudomonal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 229940034014 antimycobacterial agent Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000004957 autophagosome Anatomy 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
- 229960004988 azosemide Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940092732 belladonna alkaloid Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
- 229960003228 benzphetamine hydrochloride Drugs 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 1
- 229960000910 bethanechol Drugs 0.000 description 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 1
- 229960002123 bethanechol chloride Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 229960004645 bismuth subcitrate Drugs 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 229960002624 bretylium tosilate Drugs 0.000 description 1
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 229950007169 buciclate Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229940015694 butabarbital Drugs 0.000 description 1
- 229960002546 butalbital Drugs 0.000 description 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 1
- UULSXYSSHHRCQK-UHFFFAOYSA-N butibufen Chemical compound CCC(C(O)=O)C1=CC=C(CC(C)C)C=C1 UULSXYSSHHRCQK-UHFFFAOYSA-N 0.000 description 1
- 229960002973 butibufen Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 229960000530 carbenoxolone Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 210000004718 centriole Anatomy 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- FUFVKLQESJNNAN-RIMUKSHESA-M chembl1200851 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(O)C1=CC=CC=C1 FUFVKLQESJNNAN-RIMUKSHESA-M 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960001552 chlorprothixene Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- LZFOPEXOUVTGJS-UHFFFAOYSA-N cis-sinapyl alcohol Natural products COC1=CC(C=CCO)=CC(OC)=C1O LZFOPEXOUVTGJS-UHFFFAOYSA-N 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940119526 coniferyl alcohol Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 1
- 229950009702 darodipine Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 229950010734 demoxepam Drugs 0.000 description 1
- GGRWZBVSUZZMKS-UHFFFAOYSA-N demoxepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C[N+]([O-])=C1C1=CC=CC=C1 GGRWZBVSUZZMKS-UHFFFAOYSA-N 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 229940119751 dextroamphetamine sulfate Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 238000004720 dielectrophoresis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229950006690 dimethisterone Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940017825 dromostanolone Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229960001142 encainide Drugs 0.000 description 1
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- VBRVDDFOBZNCPF-BRSFZVHSSA-N estriol succinate Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](OC(=O)CCC(O)=O)C4)OC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VBRVDDFOBZNCPF-BRSFZVHSSA-N 0.000 description 1
- 229960003836 estriol succinate Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229950008385 estrone sulphate Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002209 ethinamate Drugs 0.000 description 1
- GXRZIMHKGDIBEW-UHFFFAOYSA-N ethinamate Chemical compound NC(=O)OC1(C#C)CCCCC1 GXRZIMHKGDIBEW-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- 229960003533 ethotoin Drugs 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 229960001460 ethylestrenol Drugs 0.000 description 1
- AOXRBFRFYPMWLR-XGXHKTLJSA-N ethylestrenol Chemical compound C1CC2=CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 AOXRBFRFYPMWLR-XGXHKTLJSA-N 0.000 description 1
- 229940012028 ethynodiol diacetate Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 229960002724 fenoldopam Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 229960001374 fluphenazine decanoate Drugs 0.000 description 1
- 229960000787 fluphenazine enanthate Drugs 0.000 description 1
- 229960001258 fluphenazine hydrochloride Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000004397 glyoxysome Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960004553 guanabenz Drugs 0.000 description 1
- HPBNRIOWIXYZFK-UHFFFAOYSA-N guanadrel Chemical compound O1C(CNC(=N)N)COC11CCCCC1 HPBNRIOWIXYZFK-UHFFFAOYSA-N 0.000 description 1
- 229960003845 guanadrel Drugs 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 229960003246 homatropine methylbromide Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- 229940065346 hydroxyprogesterone acetate Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960004053 ibutilide Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical group C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 238000000462 isostatic pressing Methods 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229950005223 levamfetamine Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 229960000589 loxapine succinate Drugs 0.000 description 1
- 229960001910 lynestrenol Drugs 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 210000002244 magnetosome Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960000606 medrogestone Drugs 0.000 description 1
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000300 mesoridazine Drugs 0.000 description 1
- CRJHBCPQHRVYBS-UHFFFAOYSA-N mesoridazine besylate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 CRJHBCPQHRVYBS-UHFFFAOYSA-N 0.000 description 1
- 229960003664 mesoridazine besylate Drugs 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 150000001247 metal acetylides Chemical class 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960002532 methamphetamine hydrochloride Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229960001470 methantheline Drugs 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- 229960002786 methenamine mandelate Drugs 0.000 description 1
- 229960002683 methohexital Drugs 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 229960000270 methylestrenolone Drugs 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229960000316 methyprylon Drugs 0.000 description 1
- 229960001980 metirosine Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- 229960004684 molindone hydrochloride Drugs 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 229960002608 moracizine Drugs 0.000 description 1
- FUBVWMNBEHXPSU-UHFFFAOYSA-N moricizine Chemical compound C12=CC(NC(=O)OCC)=CC=C2SC2=CC=CC=C2N1C(=O)CCN1CCOCC1 FUBVWMNBEHXPSU-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000003612 morphinomimetic agent Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- RLWRMIYXDPXIEX-UHFFFAOYSA-N muzolimine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C)N1N=C(N)CC1=O RLWRMIYXDPXIEX-UHFFFAOYSA-N 0.000 description 1
- 229960001788 muzolimine Drugs 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960001935 nandrolone decanoate Drugs 0.000 description 1
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002640 nordazepam Drugs 0.000 description 1
- AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 229960002831 norgestrienone Drugs 0.000 description 1
- GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 229960000464 oxandrolone Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229930015763 p-coumaryl alcohol Natural products 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 229910052699 polonium Inorganic materials 0.000 description 1
- HZEBHPIOVYHPMT-UHFFFAOYSA-N polonium atom Chemical compound [Po] HZEBHPIOVYHPMT-UHFFFAOYSA-N 0.000 description 1
- 229920000553 poly(phenylenevinylene) Polymers 0.000 description 1
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920002098 polyfluorene Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920000417 polynaphthalene Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000123 polythiophene Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000001272 pressureless sintering Methods 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 150000003195 pteridines Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 229960001424 quinestrol Drugs 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- PPKJUHVNTMYXOD-CEHYXHNTSA-N quinupristin-dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C/C(=O)NC\C=C/C(/C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)CC2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-CEHYXHNTSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 229940066293 respiratory stimulants Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 229960005009 rolitetracycline Drugs 0.000 description 1
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 238000004439 roughness measurement Methods 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- GFJWACFSUSFUOG-ZJTJBYBXSA-M sodium dehydroepiandrosterone sulfate Chemical compound [Na+].C1[C@@H](OS([O-])(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 GFJWACFSUSFUOG-ZJTJBYBXSA-M 0.000 description 1
- SONHXMAHPHADTF-UHFFFAOYSA-M sodium;2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O SONHXMAHPHADTF-UHFFFAOYSA-M 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229950009279 sorivudine Drugs 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- 229960004730 sulfabenzamide Drugs 0.000 description 1
- PBCZLFBEBARBBI-UHFFFAOYSA-N sulfabenzamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC(=O)C1=CC=CC=C1 PBCZLFBEBARBBI-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229950004351 telenzepine Drugs 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- 229960004869 thiethylperazine Drugs 0.000 description 1
- XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- NZFNXWQNBYZDAQ-UHFFFAOYSA-N thioridazine hydrochloride Chemical compound Cl.C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C NZFNXWQNBYZDAQ-UHFFFAOYSA-N 0.000 description 1
- 229960004098 thioridazine hydrochloride Drugs 0.000 description 1
- 229960000882 thiothixene hydrochloride Drugs 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 210000002377 thylakoid Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- PTNLHDGQWUGONS-UHFFFAOYSA-N trans-p-coumaric alcohol Natural products OCC=CC1=CC=C(O)C=C1 PTNLHDGQWUGONS-UHFFFAOYSA-N 0.000 description 1
- PTNLHDGQWUGONS-OWOJBTEDSA-N trans-p-coumaryl alcohol Chemical compound OC\C=C\C1=CC=C(O)C=C1 PTNLHDGQWUGONS-OWOJBTEDSA-N 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
- BXDAOUXDMHXPDI-UHFFFAOYSA-N trifluoperazine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 BXDAOUXDMHXPDI-UHFFFAOYSA-N 0.000 description 1
- 229960000315 trifluoperazine hydrochloride Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
- 229960004161 trimethobenzamide Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- UHLOVGKIEARANS-QZHINBJYSA-N tripamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(=O)NN2C[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3C2)=C1 UHLOVGKIEARANS-QZHINBJYSA-N 0.000 description 1
- 229950004678 tripamide Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229960005088 urethane Drugs 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/44—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes for electrophoretic applications
- C09D5/448—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes for electrophoretic applications characterised by the additives used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/02—Emulsion paints including aerosols
- C09D5/024—Emulsion paints including aerosols characterised by the additives
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
- C09D7/40—Additives
- C09D7/65—Additives macromolecular
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D13/00—Electrophoretic coating characterised by the process
- C25D13/04—Electrophoretic coating characterised by the process with organic material
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D13/00—Electrophoretic coating characterised by the process
- C25D13/18—Electrophoretic coating characterised by the process using modulated, pulsed, or reversing current
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
Definitions
- the present invention relates generally to the process of the deposition of 1) colloidal particles suspended in an aqueous medium or in an aqueous medium slurry or 2) organic or metallo-organic molecules dissolved in an aqueous medium, (preferably concentrated systems and most preferably highly concentrated systems) under the influence of an electric field onto an electrode or porous substrate placed in front of an electrode.
- the present invention relates to a controllable system and method for electrophoretic deposition in unbalanced AC electric fields (UAC-EPD) to form smooth deposits with no visible defects or to form a coating or a deposit.
- UAC-EPD unbalanced AC electric fields
- Electrophoretic deposition is a colloidal processing technique in which a suspension or solution of charged particles or charged organic or metallo-organic molecules is placed in an electric field. The charged particles move towards one of the electrodes (electrophoresis) and subsequently form a deposit on this electrode (deposition) see VanderBiest, O. & Vandeperre, L. J. Electrophoretic deposition of materials. Annual reviews of material science 29, 327-352 (1999). From environmental, economical and technical point of view water is the ideal solvent. Since water covers 2/3 of the earth's surface and its is involved in all biological processes in living cells and life on earth dependents on it; it is an ideal solvent for many natural molecules.
- water is the basic protonic solvent.
- the higher degree of dissociation ensures a more efficient charging of all pH sensitive particle surface groups and hence adds to the higher mobility in water at a given acid concentration.
- a final less obvious advantage of aqueous suspensions is the vast amount of knowledge on the behaviour of particles in aqueous media. Since water based systems are preferred in production environment most additives, such as binders and dispersants, have been optimized for water. Water would therefore be the solvent of choice for electrophoretic deposition, but for the electrolytic decomposition of water. Most EPD is therefore carried out in non-aqueous solvents, direct current electrophoretic deposition from water being limited to low electric fields.
- WO 2004/052489A describes a method of attaching a nanostructure-containing material onto a sharp tip of an object, the method comprising: (i) forming a suspension of nanostructure-containing material in a liquid medium; (ii) immersing at least one electrode in the suspension; (iii) placing the sharp tip into the suspension; and (iv) applying a direct or alternating current to the immersed electrode and the sharp tip causing at least a portion of the nanostructure-containing material in the suspension to become attached to the object proximate at apex of the sharp tip.
- WO 2004/052489A discloses a dielectrophoresis method.
- JP 52-056143A describes alternating current electrodeposition coating using an aqueous paint containing a salt of a purified polycarboxylic acid resin as binder.
- DD 215338 Al describes electrophoretic precipitation from a suspension using asymmetrical alternating voltage in which the negative portion is 1 to 25% of the maximum value of the positive voltage (by superimposing DC signal onto an AC signal) to improve coating e.g. of ceramic moulds. As a result unwanted electrochemical reactions were slowed down, yet not fully stopped. DD 215338A1 reported that the electrochemical dissolution of the electrodes was reduced
- GB 253091A describes a method of depositing- organic material electrically on or in a fabric which comprises placing the fabric on the outer surface of a gas-permeable anode in contact with an aqueous electroconducting emulsion of the organic material to be deposited, passing a depositing current through the emulsion and the anode and withdrawing the gas formed at the outer surface of the anode through the anode by causing a lower pressure to be exerted on its inner surface than on its outer surface.
- the current should preferably be an effectively unidirectional one, it may be a current of constant value, or a direct current of pulsating character and in some instances it is useful to employ an unbalanced alternating current, which is most conveniently obtained by superimposing an alternating current upon a direct current.
- US 1,589,327 describes a process of depositing a cellulosic compound on an electroconducting surface of an object, which comprises the steps of bringing said surface into contact with an electroconducting emulsion containing droplets of the cellulosic compound and passing a depositing electric current through said surface and emulsion.
- US 1589327 further describes that for some purposes it may be convenient to employ a considerably unbalanced alternating current.
- the present invention concerns an electrophoretic deposition (EPD) process in reduced or limited water electrolysis in an aqueous environment characterized in that the process involves subjecting positively or negatively charged or partially charged molecules or colloidal particles to an unbalanced alternating current (UAC) electric fields for depositing molecules or particles in aqueous medium from the aqueous medium onto an electrode or porous substrate placed in front of an electrode.
- UAC-EPD unbalanced alternating current
- UAC unbalanced alternating current
- UAC unbalanced alternating current
- UAC unbalanced alternating current
- bioactive agents in thin coatings or in thick coatings (micrometer scale average thickness) from an aqueous medium onto a conductive medium or electrode or porous substrate placed in front of an electrode by subjecting them to unbalanced alternating current (UAC) electric to reduce or prevent electrolysis of water in the aqueous medium.
- UAC unbalanced alternating current
- the present invention further concerns a system of high voltage EPD of colloidal particles suspended in an aqueous medium while the decomposition of water is suppressed below the point of gas bubble formation.
- the current problem in the art of high voltages water decomposition is solved by applying an unbalanced alternating electric field. Contrary to what one might expect, the particles form an adhering deposit on the selected electrodes (deposition electrodes), the experimental results of present invention clearly demonstrated that by present invention deposits with high green density (> 60 % in the case of monomodal spherical submicron Alumina particles) and smooth surface can be formed from aqueous suspensions.
- Defect-free high density green deposits can be obtained from aqueous suspensions if the electrolysis of water is avoided.
- the quality of these deposits is equal or better than those produced in the past by conventional electrophoretic deposition from alcohol based suspensions.
- the deposition mechanics still exhibit a linear increase of deposit yield and no self limiting behaviour was observed, suggesting the possibility of limitless thickness.
- the invention is broadly drawn to an unbalanced AC electric fields (UAC-EPD) process for depositing amphoteric substance or self-charging compounds in aqueous solutions under the influence of an unbalanced AC electric field onto an electrode or porous substrate placed in front of an electrode or for depositing colloidal particles with an electric charge or that comprise charged metallo-organic molecules dissolved or suspended in an aqueous medium or an aqueous slurry.
- UAC-EPD is preferably carried out using concentrated systems and most preferably using highly concentrated systems. In diluted solutes or suspended systems, the particles can move independently from one another.
- the electrophoretic deposition (EPD) process for depositing charged, partially charged or self-charging compounds or organic or metallo- organic molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to unbalanced alternating current (UAC) electric fields.
- UAC unbalanced alternating current
- Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged metallo-organic molecules dissolved or suspended in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to an unbalanced AC- signal that has a voltage evolution of which the positive and negative amplitude differ in absolute value
- Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to an AC-signal of which the shape of the negative and positive signal part differ, preferably in amplitude and most preferably in both amplitude and duration and whereof the net resulting DC-signal of said unbalanced signal, obtained by calculating the voltage average over one period, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
- EPD electrophoretic deposition
- Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged metallo-organic molecules dissolved or suspended in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to a signal in which the amplitude differs significantly for the positive and negative part, while maintaining a net integral over one period of lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
- EPD electrophoretic deposition
- Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to an UAC fields as depicted in figure 1.
- EPD electrophoretic deposition
- Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to an unbalanced AC electric fields of one symmetrical sinus waves on top of another symmetrical sinus wave with an integral of lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one time period
- Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to AC-fields that have an unbalanced form, yet yielding no net DC signal.
- EPD electrophoretic deposition
- Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to unbalanced AC electric fields that are composed of signals with different amplitudes for the negative and the positive part but with an integral of lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one time period. It can be AC fields in which the amplitude and the duration of the negative and the positive part differ, but the overall integral over one period is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
- unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention as described above is used to coat or paint a device or instrument for instance to coat a medical prostheses, an orthopaedic implant, dental endodontic or dental implant.
- UAC- EPD unbalanced alternating current electrophoretic deposition
- Another aspect of the invention is the use of unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention to remove said charged or self-charging compounds or molecules form an aqueous medium.
- the unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention to produce a strong lightweight metals and alloys.
- the unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention to produce a food or a feed.
- Another aspect of the invention is the use of asymmetric alternating current electrophoretic deposition (UAC- EPD) of present invention to form smooth deposits with no visible defects or the use of asymmetric alternating current electrophoretic deposition (UAC- EPD) of any of present to form deposits with a smooth surface of a Ra of 10 to 50 ⁇ m, preferably a Ra of 10 to 10000 nm, more preferably a Ra of 10 to 500 nm, and most preferably a Ra of 10 -200 nm.
- a further aspect is the realisation of a deposit with high green density > 30 %, preferably a deposit with high green density > 50 % or most preferably a deposit with high green density > 60 % produced by such process.
- unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention as described above is used to produce a device or instrument for instance to produce a medical prostheses, an orthopaedic implant, dental endodontic or dental implant.
- a coating process comprising the steps of: immersing an electrode or porous substrate placed in front of an electrode in an aqueous medium comprising charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles and subjecting said charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles in an aqueous medium to (asymmetric) unbalanced alternating current (UAC) electric fields, having a frequency and a positive and negative part each having an amplitude and a duration, to deposit electrophoretically said charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles onto said electrode or porous substrate placed in front of an electrode, characterised in that said amplitude of said unbalanced alternating current (UAC) electric field differs significantly for the positive and negative part, while maintaining a net integral of the applied signal over one period, i.e.
- UAC unbalanced alternating current
- average potential is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
- An electrical field must be realised between the counter electrode and the electrode in the aqueous medium comprising charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles for electrophoretic deposition to occur. This can also be realised with the counter electrode outside the vessel containing the aqueous medium, if an electric field can still be realised between the counter electrode and the electrode in the medium.
- aspects of the present invention are also realized by a system for electrocoating a conductive substrate with organic or metallo-organic molecules or particles in which said system coats said conductive substrate with at least one layer or coating at a controllable average thickness in the nm or in the ⁇ m scale from a suspension in an aqueous working medium of one or more types of said organic or metallo-organic molecules or particles, wherein said system comprises a power supply connected to a signal generator to generate between a counter electrode and said conductive substrate, an unbalanced alternating current (AC) signal, said signal having a frequency and a positive and negative part each having an amplitude and a duration, in which said amplitudes for said positive and negative parts differ significantly, while maintaining a net integral of the applied voltage over one period, i.e.
- AC alternating current
- said system comprises a control system connected to said signal generator for determining the frequency and amplitude of said unbalanced AC signal.
- Fig. 1 is a schematic view showing one period of the applied unbalanced AC signal V is the voltage and t, the time.
- Fig. 2 demonstrates OC-AI 2 O 3 Deposits formed using (a) 100 V DC for 1200 s or (b) a 50
- Fig. 3 is a schematic view of the deposition rate, D, of OC-AI 2 O 3 versus the asymmetry factor, A, of the applied signal.
- V 1 , V 2 , t l5 1 2 are defined in Figure 1.
- the suspension consisted of a 200 g/L SM8 in water containing 4.10-4 M HNO 3 .
- Fig. 4 demonstrates the particle size distribution of SM8 powder measured by light scattering (Mastersizer micro+, Malvern) as volume, v, versus particle diameter, d.
- Fig. 5 is a micrograph of SM8 ⁇ - Al 2 O 3 powder
- Fig. 6 demonstrates the electrophoretic mobility, E, of SM8 alumina as a function of operational pH for different solvent combinations: water (dashes), ethanol with 5 vol.
- Fig. 7 shows the deposition of polystyrene particles from an isopropanol suspension in a 50 Hz unbalanced AC-field with an asymmetry factor of 4.
- Fig. 8 demonstrates the dependence of the deposition yield, Y, upon frequency, f, and time, t, for a 200 g/L Al 2 O 3 (SM8, Baikowski) suspension containing 4 10 "4 M HNO 3 in an unbalanced 500 V peak to peak field with an asymmetry factor of 4. Each experiment was repeated 3 times. The diamonds represent the time dependence at 50 Hz and the dots represent the frequency dependence after 40 minutes.
- Fig. 9 displays the temperature, T, as a function of time, t, during electrophoretic deposition for AC-EPD in water (dashes), AC-EPD in ethanol (full line) and DC- EPD in ethanol (dots).
- Fig. 10 provides a picture of the surface roughness of a deposit prepared by electrophoretic deposition of a 200 g/L SM8 ethanol suspension with 1 10 "3 M HNO 3 and deposited at 200 V DC for 20 minutes
- Fig. 11 provides a picture of the surface roughness of a deposit prepared by electrophoretic deposition of a 200 g/L SM8 Water suspension with 4 10 "4 M HNO 3 and deposited at 50 Hz 500 Vp-p for 20 minutes.
- Fig. 12 Example of an applied signal as measured during deposition (Fluke 97 scopemeter equipped with a voltage divider with a division factor of 100).
- Fig. 13 Example of ⁇ -alumina (SM8 grade, Baikowski) deposit made using the signal as shown in Fig. 12.
- Fig. 14 provides the droplet size distribution as volume fraction, vf, versus droplet diameter, d D , as measured using light scattering after 30 minutes stirring. All measured systems were prepared using 40 ml of aqueous suspension and 40 ml of cyclohexane, while the mass of stabilizing powder and the volume of charging agent (0.5M propionic acid) was varied: O.lg SM8/0.05 ml propionic acid (grey dashes with 2 peaks), 0.5g SM8/0.1 ml propionic acid (black dashes with 2 peaks), Ig
- Fig. 15 Schematic representation of a) the EPD cell in which 1 is a deposition electrode, 2 is a pump and 3 is a suspension and emulsion reservoir and b) the applied unbalanced AC signal as a function of voltage, V, upon time, t, with an amplitude of 500 Vp-p and a frequency of 50 Hz.
- Fig. 16 Micrographs of polished cross-sections of Alumina grades A (a), B (b), C(c) and E (d) after sintering (see Table 1 and 2)
- Fig. 17 Solid particle stabilized emulsion droplet, where L A is liquid A, L B is liquid B, 4 is the inter-phase and P is a solid particle.
- Fig. 18 Typical example of an unbalanced AC-signal generated by a function generator as voltage, V, versus time, t, in ms. The ratios V2/V1 and tl/t2 are equal to ensure the elimination of a net DC- signal.
- Fig. 19 Unbalanced AC-signal as voltage, V, versus time, t, composed from two symmetrical sinus waves shifted 90° in phase and with a frequency ratio of 2.
- first, second, third and the like in the description and in the claims are used for distinguishing between similar elements and not necessarily for describing a sequence, either temporally, spatially, in ranking or in any other manner. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein. Moreover, the terms top, bottom, over, under and the like in the description and the claims are used for descriptive purposes and not necessarily for describing relative positions. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other orientations than described or illustrated herein.
- Coupled and “connected”, along with their derivatives, may be used. It should be understood that these terms are not intended as synonyms for each other. Thus, the scope of the expression “a device A coupled to a device B” should not be limited to devices or systems wherein an output of device A is directly connected to an input of device B. It means that there exists a path between an output of A and an input of B which may be a path including other devices or means. “Coupled” may mean that two or more elements are either in direct physical or electrical contact, or that two or more elements are not in direct contact with each other but yet still co-operate or interact with each other.
- any of the claimed embodiments can be used in any combination.
- some of the embodiments are described herein as a method or combination of elements of a method that can be implemented by a processor of a computer system or by other means of carrying out the function.
- a processor with the necessary instructions for carrying out such a method or element of a method forms a means for carrying out the method or element of a method.
- an element described herein of an apparatus embodiment is an example of a means for carrying out the function performed by the element for the purpose of carrying out the invention.
- a molecule in the meaning of this invention is sufficiently stable group of at least two atoms in a definite arrangement held together by very strong chemical bonds, comprising the charged or self-charging molecules and the charged organic molecules and biomolecules.
- bio-active agent as used herein broadly includes any compound, composition of matter, or mixture thereof, that has biological activity and can be delivered in the subject, preferably a mammal, to whom it is administered.
- a biomolecule is any organic molecule that is produced by living organisms, including large polymeric molecules such as proteins, polysaccharides, and nucleic acids as well as small molecules such as primary metabolites, secondary metabolites, and natural products.
- biomolecules comprise primarily carbon and hydrogen, nitrogen, and oxygen, and, to a smaller extent, phosphorus and sulphur. Other elements sometimes are incorporated but are much less common.
- Typical biomolecules are of the group of the nucleosides and nucleotides, the saccharides, lignin, lipids, amino acids, protein structures (for vitamins.
- biomolecules include: small molecules (lipid, phospholipids, glycolipid, sterol, vitamin, hormone, neurotransmitter, carbohydrate, sugar, disaccharide) monomers (amino acids, nucleotides, monosaccharides), polymers (peptides, oligopeptides, polypeptides, proteins, nucleic acids, i.e. DNA, RNA oligosaccharides, polysaccharides (including cellulose) and lignin.
- small molecules lipid, phospholipids, glycolipid, sterol, vitamin, hormone, neurotransmitter, carbohydrate, sugar, disaccharide
- monomers amino acids, nucleotides, monosaccharides
- polymers peptides, oligopeptides, polypeptides, proteins
- nucleic acids i.e. DNA, RNA oligosaccharides, polysaccharides (including cellulose) and lignin.
- Nucleosides are molecules formed by attaching a nucleobase to a ribose ring. Examples of these include cytidine, uridine, adenosine, guanosine, thymidine and inosine. Nucleosides can be phosphorylated by specific kinases in the cell, producing nucleotides, which are the molecular building blocks of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). DNA or RNA has a negative charge.
- Monosaccharides are the simplest form of carbohydrates with only one simple sugar. They essentially contain an aldehyde or ketone group in their structure. Examples of monosaccharide are the hexoses glucose, fructose, and galactose and pentoses, ribose, and deoxyribose Disaccharides are formed when two monosaccharides, or two single simple sugars, form a bond with removal of water. Examples of disaccharides include sucrose, maltose, and lactose.
- Polysaccharides are polymerized monosaccharides, complex, carbohydrates. They have multiple simple sugars. Examples are starch, cellulose, and glycogen. They are generally large and often have a complex branched connectivity. Shorter polysaccharides, with 2 - 10 monomers, are called oligosaccharides.
- Lignin is a random polymer composed mainly of aromatic rings with short (up to three) aliphatic carbons chains connecting the rings. Lignin is the second most common biopolymer (after cellulose) and is one of the primary structural components of most plants. It contains subunits derived from p- coumaryl alcohol, coniferyl alcohol, and sinapyl alcohol and is unusual among biomolecules in that it is racemic i.e.
- Lipids are chiefly fatty acid esters, and are the basic building blocks of biological membranes. Another biological role is energy storage (e.g., triglycerides). Most lipids consist of a polar or hydrophilic head (typically glycerol) and one to three nonpolar or hydrophobic fatty acid tails, and therefore they are amphiphilic.
- the hydrophilic head is from one of three classes: Glycolipids, whose heads contain an oligosaccharide with 1-15 saccharide residues; Phospholipids, whose heads contain a positively charged group that is linked to the tail by a negatively charged phosphate group; and Sterols, whose heads contain a planar steroid ring, for example, cholesterol.
- Other lipids include prostaglandins and leukotrienes which are both 20-carbon fatty acyl units synthesized from arachidonic acid. They are also known as fatty acids
- Fatty acids consist of unbranched chains of carbon atoms that are connected by single bonds alone (saturated fatty acids) or by both single and double bonds (unsaturated fatty acids).
- the chains are usually 14-24 carbon groups long, but it is always an even number.
- Amino acids contain both amino and carboxylic acid functional groups. (In biochemistry, the term amino acid is used when referring to those amino acids in which the amino and carboxylate functionalities are attached to the same carbon, plus proline which is not actually an amino acid).
- Amino acids are the building blocks of long polymer chains. With 2-10 amino acids such chains are called peptides, with 10-100 they are often called polypeptides, and longer chains are known as proteins. These protein structures have many structural and enzymatic roles in organisms.
- amino acids There are twenty amino acids that are encoded by the standard genetic code, but there are more than 500 natural amino acids. When amino acids other than the set of twenty are observed in proteins, this is usually the result of modification after translation (protein synthesis). Only two amino acids other than the standard twenty are known to be incorporated into proteins during translation, in certain organisms: Selenocysteine is incorporated into some proteins at a UGA codon, which is normally a stop codon. Pyrrolysine is incorporated into some proteins at a UAG codon. For instance, in some methanogens in enzymes that are used to produce methane. Besides those used in protein synthesis, other biologically important amino acids include carnitine (used in lipid transport within a cell), ornithine, GABA and taurine.
- Proteins have several well- classified elements of local structure formed by intermolecular attraction, which forms the secondary structure of protein. They are broadly divided in two, alpha helix and beta sheet, also called beta pleated sheets.
- Alpha helices are formed of coiling of protein due to attraction between the amine group of one amino acid with the carboxylic acid group of another amino acid. The coil contains about 3.6 amino acids per turn and the alkyl group of amino acid lie outside the plane of coil.
- Beta pleated sheets are formed by strong continuous hydrogen bond over the length of protein chain. Bonding may be parallel or antiparallel in nature. Structurally, natural silk is formed of beta pleated sheets.
- a protein is formed by action of both these structures in variable ratios. Coiling may also be random.
- the overall 3D structure of a protein is termed its tertiary structure. It is formed as result of various forces like hydrogen bonding, disulphide bridges, hydrophobic interactions, hydrophilic interactions, van der Waals force etc.
- quaternary structure of protein is formed.
- Quarternary structure is a unique attribute of polymeric and heteromeric proteins like haemoglobin, which consists of two alpha and two beta peptide chains.
- a vitamin is a compound that is generally not synthesized by a given organism but is nonetheless vital to its survival or health. These compounds must be absorbed, or eaten, but typically only in trace quantities.
- the frequency of said unbalanced signal or UAC lies between 0.1 Hz and 1 MHz, preferably between 1 Hz and 1 kHz and most preferably between 10 Hz and 200 Hz.
- the frequency of said unbalanced signal or UAC has an applied signal strength lies between 1 V peak to peak and 10000V, preferably between IV and 5000 V peak to peak, more preferably between 10V and 5000V peak to peak, most preferably between 10 V peak to peak and 2000V peak to peak and especially preferably between 50 V peak to peak and 1000 V peak to peak.
- the resulting electric field strength calculated as the voltage over the interelectrode distance, lies between 100 V/m and 10 6 V/m, preferable between 1000 V/m and 10 5 V/m and most preferably between 2500 V/m and 25000 V/m.
- the present invention solves the problems of high voltage EDP from water in the related art by method for electrophoretic deposition in unbalanced AC electric fields (UAC-EPD).
- Unbalanced (asymmetric) AC electric fields (UAC) can be achieved by creating a signal in which the amplitude differs significantly for the positive and negative part, while maintaining a net integral over one period lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero,.
- Such UAC fields as depicted in figure 1.
- the Unbalanced AC electric fields do not necessary need to have triangle form wave form.
- one sinus waves on top of another sinus wave with an integral lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one time period can be used and easily enforced without sudden changes
- Such AC fields have an unbalanced form, yet yield no net DC signal.
- unbalanced AC electric fields can be described as an AC electric field that is composed of signals with different amplitudes for the negative and the positive part but with an integral lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one time period. It can be AC fields in which the amplitude and the duration of the negative and the positive part differ, but the overall integral over one period is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero,.
- the unbalanced AC-signal of present invention for depositing colloidal particles suspended in an aqueous medium or molecules in solution of an aqueous medium has a voltage evolution of which the positive and negative amplitude differ in absolute value. Yet over one period of the signal the net DC-voltage, calculated by integrating the voltage in function of time, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
- An unbalanced AC-signal is a signal of which the shape of the negative and positive signal part differ, preferably in amplitude and most preferably in both amplitude and duration. However the net resulting DC-signal of said unbalanced signal, obtained by calculating the voltage average over one period, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
- the unbalances can take different shapes such as triangle, sine; square or others.
- a first and foremost option to generate unbalanced AC-signals is the use of a function generator. Any general shape of wave can be obtained in this manner. Care has to be taken to ensure that the voltage or current integral over one period is below the threshold for gas bubble evolution. In other words the absolute area below the positive end negative part of one signal period have to be of such size that the difference between them yields a absolute net voltage over one period smaller than 4V and preferably equal to zero.
- Fig 18 shows a typical example of a wave composed of two triangles. Similar results can be obtained with block waves, trapezoidal waves or waves with rounded features. When utilizing amplifiers one must however take care that the wave offered to the amplifiers input is not distorted during amplification in such a manner that a net DC- signal is generated.
- a second option is to compose an unbalanced AC-signal by superimposing two symmetrical signals, which are shifted in phase and have different frequencies, on one another. Since both original signals are symmetrical and have a net DC-value of zero the resulting composed signal also has a net DC-signal equal to zero (Fig. 19)
- E 1+2 (t) Ei x sin ( ⁇ t) + m E 2 x sin (n ⁇ t + ⁇ )
- Ei and E 2 the amplitudes of the original signals, ⁇ the angular velocity, ⁇ the phase shift and m and n two arbitrary multiplication factors of which n differs from 1.
- the amplitude of the negative peak is almost twice the size of the amplitude of the positive signal.
- Table 3 yields of alumina (SM8 grade, Baikowski) deposit made using the signal as shown in Fig. 12
- UAC-EPD is an electrophoretic deposition or the process that colloidal particles suspended in a liquid medium or solved molecules in a liquid medium migrate and are deposited under the influence of the UAC fields onto an electrode or porous substrate placed in front of an electrode.
- Such UAC-EPD can include or can be used for electrocoating, cathodic electrodeposition, electrophoretic coating, or electrophoretic painting.
- FIG. 1 Examples of AC-fields that have an unbalanced form, yet yielding no net DC signal, are shown in Fig. 1.
- the amplitude and duration of the negative and positive part differ, but the overall integral over one period is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
- Electrophoretic deposition of OC- Al 2 O 3 powder in water using the unbalanced AC signal represented in Fig. 1 resulted in smooth deposits with no visible defects.
- the surface quality of the deposits is comparable to that of deposits made from non-aqueous (ethanol, acetone) systems using a DC field.
- the deposits obtained from an aqueous suspension using a DC and unbalanced AC fields are compared in Fig. 2, clearly revealing the effect of water electrolysis in case of the DC- electrical field, the AC-electrical field the superimposition of AC on DC field.
- the unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode is particularly suitable for the deposition of inorganic substances such as hydroxides, oxides (including glasses), carbides, nitrites, borides, carbonates, carbonitrides, metals, phosphors, phosphates, hydrates, hydrides, fluorides, sulphides, sulphates, salts and apatites some of which can be bioactive or can be biocompatible.
- inorganic substances such as hydroxides, oxides (including glasses), carbides, nitrites, borides, carbonates, carbonitrides, metals, phosphors, phosphates, hydrates, hydrides, fluorides, sulphides, sulphates, salts and apatites some of which can be bioactive or can be biocompatible.
- the unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous medium onto an electrode or porous substrate placed in front of an electrode is particularly suitable for the deposition of organics such as monomers, precursors, hydrocarbons, functional hydrocarbons, macromolecules, oligosaccharides, polysaccharides, polymers (e.g. thermoplastic polymers, thermo curing polymers, biopolymers, alginates, carrageen or other algae derived polymers, kollicoat IR, or resins, oligomers some of which can be bioactive and others biocompatible.
- organics such as monomers, precursors, hydrocarbons, functional hydrocarbons, macromolecules, oligosaccharides, polysaccharides, polymers (e.g. thermoplastic polymers, thermo curing polymers, biopolymers, alginates, carrageen or other algae derived polymers, kollicoat IR
- the unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous medium onto an electrode or porous substrate placed in front of an electrode is particularly suitable for the deposition of proteins (e.g. collagen), polynucleotides (e.g. DNA or RNA), sugars, fatty acids, amino acids, nucleotides.
- proteins e.g. collagen
- polynucleotides e.g. DNA or RNA
- sugars e.g. DNA or RNA
- the unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous medium onto an electrode or porous substrate placed in front of an electrode is particularly suitable for the deposition of eukaryote or prokaryote cells. It can for instance be used for the deposition of amoeba, bacteria, yeast, plant cells, mammalian cells (e.g. human cells for instance osteoblasts) fungae, and of the organelles, cell components and macromolecules thereof. It is particularly interesting that these cells organelles, cell components and macromolecules thereof are bioactive.
- Negatively charged molecules are present in biological systems.
- the "negatively charged molecules” are meant to include molecules such as nucleic acid molecules (e.g., RNA, DNA, oligonucleotides, mixed polymers, peptide nucleic acid, and the like), peptides (e.g., polyaminoacids, polypeptides, proteins and the like).
- Nucleotides, pharmaceutical and biological compositions have negatively charged groups that can ion- pair with the positively charged head group of the cationic lipids of the invention.
- the charge or isoelectric point (pi) can be changed. For example, the chemical conversion of surface carboxyl groups of antibodies to extended primary amino groups results in the cationization of the antibody.
- Nonglycolated Fab pL>9.3
- Food is made up of many different chemical components or parts, including vitamins, minerals, sugars, fibres, water, lipids, proteins and starches. In addition to these main nutrient components, many foods contain smaller amounts of biologically active chemicals. In plants, these are referred to as phytochemicals. scientistss can separate out all of these different components of foods.
- a food portion contains negatively charged molecules and positively charged molecules which by the present method of the invention can be deposited on a conductive substrate in a smooth coating and a desired thickness. Many food items contain anionic polymers.
- Suitable cationic polymers are for instance selected from the group of cationic polyamines in particular, poly lysine (a polyamine that is almost completely protonated at physiological pH of 7.5), polyacrylamide, homopolymer of dimethyldiallyl ammonium chloride, 2-methacryloyloxyethyl trimethyl ammonium methosulfate, methacrylamido propyl trimethyl ammonium chloride, ethyleneimine, copolymers of acrylamide, cationic polyacrylic, dimethyldiallyl ammonium chloride, methacrylamido propyl trimethyl ammonium chloride, 2-methacryloyloxyethyl trimethyl ammonium methosulfate, Cl 8 trimethyl ammonium chloride, C18(polyoxyethylene) methyl ammonium chloride, pDMAEMA [(poly(dimethylamino)ethyl methylacrylate], chitosan, Linear pEI, PVP, DEAE-dextra
- Chitosan is one of a few natural cationic polysaccharides that are harmless, and it has several potential functions such as antimicrobial activity.
- the present invention can be used to make a coat or smooth objects of chitosan. Since the majority of the waterborne bacteria and virusses have a negative charge, positive charged cationic films produced by the unbalanced alternating current (UAC) electric signals method of present invention can be used to attract such and remove them.
- UAC unbalanced alternating current
- Typical anionic polymers are the polymers of the group consisting of poly- L- glutamate, anionic acrylic polymers, hydrogels based on anionic urethane polyether-amine polyelectrolytes, polymers of anionic urethane, carbomer and polyvinyl acetate phthalate [PVAP], Eudragit S, Eudragit L 100-55, sodium carboxymethylcellulose, dextran sulfate and Nafion®-117.
- Hyaluronic acid HA is the simplest glycosaminoglycan (a class of negatively charged polysaccharides).
- anionic polymers There are many natural anionic polymers that are obtainable by the purification method of Sainz-Serp, D ; Wandrey, C: Minerva Biotechnol., 2005, p. 215-229.
- Anionic polymers inhibit fibrosis, scar formation and surgical adhesions and the present method is suitable for the formation of smooth coating of such anionic polymers on medical implants, hydrogels containing carboxylate anions such as copolymer of 2-hydroxyethyl methacrylate and sodium methacrylate, anionic polymers derived from L-tyrosine.
- Several negatively charged microorganisms responsible for plaque generation and the negatively charged films have a mutual repulsion effect.
- Polio virus has an isoelectric point at a pH of about 7 such that only at alkaline pH will the polio virus have a negative charge.
- the electrokinetic property of an intact cell generally dependents upon the surface property of cells.
- the objects or coating produced by the process of present invention can comprise any bio-active compound that is suitable that is ionised, partially ionised or self charging of the various therapeutic classes of bio-active agents that can be administered while using the present dosage forms include, but are not limited to: analgesic agents; anesthetic agents; antiarthritic agents; respiratory drugs; anticancer agents; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics and antiviral agents; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastic agents; anti-Parkinson drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents and other gastrointestinally active agents; antiviral agents; anxiolytics; appetite suppressants;
- Gastrointestinally active agents that can be used to be comprised in the objects or coatings according to the method of present invention include agents for inhibiting gastric acid secretion such as, but not limited to, the H2 receptor antagonists cimetidine, ranitidine, famotidine, and nizatidine, the H+ or K+-ATPase inhibitors (also referred to as "proton pump inhibitors”) omeprazole and lansoprazole, and antacids such as, but not limited to, calcium carbonate, aluminum hydroxide and magnesium hydroxide. Also included within this general group are agents for treating infection with Helicobacter pylori (H.
- pylori such as, but are not limited to, metronidazole, tinidazole, amoxicillin, clarithromycin, tetracycline, thiamphenicol and bismuth compounds (e.g. bismuth subcitrate and bismuth subsalicylate).
- Other gastrointestinally active agents that can be administered while using the present dosage forms include, but are not limited to, pentagastrin, carbenoxolone, sulfated polysaccharides such as sucralfate, prostaglandins such as misoprostol, and muscarinic antagonists such as pirenzepine and telenzepine.
- antidiarrheal agents antiemetic agents and prokinetic agents such as, but are not limited to, ondansetron, granisetron, metoclopramide, chlorpromazine, perphenazine, prochlorperazine, promethazine, thiethyl-perazine, triflupromazine, domperidone, trimethobenzamide, cisapride, motilin, loperamide, diphenoxylate and octreotide.
- Anti-microbial agents that can be used to be comprised in the objects or coatings according to the method of present invention include tetracycline antibiotics and related compounds (e.g.
- penicillins e.g., penicillin G, penicillin VK
- antistaphylococcal penicillins e.g. cloxacillin, dicloxacillin, nafcillin and oxacillin
- aminopenicillins such as ampicillin and amoxicillin, and antipseudomonal penicillins such as carbenicillin
- cephalosporins e.g. cefadroxil, cefepime, cephalexin, cefazolin, cefoxitin, cefotetan, cefuroxime, cefotaxime, ceftazidime and ceftriaxone
- carbapenems such as, but not limited to, imipenem, meropenem and aztreonam
- aminoglycoside antibiotics such as, but not limited to, streptomycin, gentamicin, tobramycin, amikacin and neomycin
- glycopeptide antibiotics such as teicoplanin
- sulfonamide antibiotics such as, but not limited to, sulfacetamide, sulfabenzamide, sulfadiazine, sulfadoxine, sulfamerazine, sul
- Anti-diabetic agents that can be used to be comprised in the objects or coatings according to the method of present invention include, by way of example, acetohexamide, chlorpropamide, ciglitazone, gliclazide, glipizide, glucagon, glyburide, miglitol, pioglitazone, tolazamide, tolbutamide, triampterine, and troglitazone.
- Non-opioid analgesic agents that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, apazone, etodolac, difenpiramide, indomethacin, meclofenamate, mefenamic acid, oxaprozin, phenylbutazone, piroxicam and tolmetin.
- Opioid analgesics that may be used in this invention include, but are not limited to, alfentanil, buprenorphine, butorphanol, codeine, drocode, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene, sufentanil and tramadol.
- Anti-inflammatory agents that can be used to be comprised in the objects or coatings according to the method of present invention include non-steroidal anti-inflammatory agents, e.g.
- propionic acid derivatives such as, but not limited to, ketoprofen, flurbiprofen, ibuprofen, naproxen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, alminoprofen, butibufen, fenbufen, apazone, diclofenac, difenpiramide, diflunisal, etodolac, indomethacin, ketorolac, meclofenamate, nabumetone, phenylbutazone, piroxicam, sulindac and tolmetin.
- ketoprofen such as, but not limited to, ketoprofen, flurbiprofen, ibuprofen, naproxen, fenoprofen, benoxaprofen, indoprofen, pirprofen,
- Suitable steroidal anti-inflammatory agents include, but are not limited to, hydrocortisone, hydrocortisone-21-monoesters (e.g. hydrocortisone-21-acetate, hydrocortisone-21-butyrate, hydrocortisone-21 -propionate, hydrocortisone-21 -valerate), hydrocortisone- 17, 21-diesters (e.g. hydrocortisone- 17,21 - diacetate, hydrocortisone-17-acetate-21-butyrate, hydrocortisone-17,21-dibutyrate), alclometasone, dexamethasone, flumethasone, prednisolone and methylprednisolone.
- hydrocortisone hydrocortisone-21-monoesters
- hydrocortisone-21-butyrate e.g. hydrocortisone-21-propionate, hydrocortisone-21 -valerate
- hydrocortisone- 17, 21-diesters e.g.
- Anticonvulsant agents that can be used to be comprised in the objects or coatings according to the method of present invention, by way of example, azetazolamide, carbamazepine, clonazepam, clorazepate, ethosuximide, ethotoin, felbamate, lamotrigine, mephenyloin, mephobarbital, phenyloin, phenobarbital, primidone, trimethadione, vigabatrin, topiramate, and benzodiazepines.
- CNS and respiratory stimulants that can be used to be comprised in the objects or coatings according to the method of present invention, but are not limited to, xanthines such as caffeine and theophylline; amphetamines such as amphetamine, benzphetamine hydrochloride, dextroamphetamine, dextroamphetamine sulfate, levamphetamine, levamphetamine hydrochloride, methamphetamine, and methamphetamine hydrochloride; and miscellaneous stimulants such as methylphenidate, methylphenidate hydro-chloride, modafinil, pemoline, sibutramine and sibutramine hydrochloride.
- Neuroleptic agents that can be used to be comprised in the objects or coatings according to the method of present invention include antidepressant drugs, antimanic drugs and antipsychotic agents. Suitable antidepressant drugs include:
- tricyclic antidepressants such as, but not limited to, amoxapine, amitriptyline, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline and trimipramine,
- serotonin re-uptake inhibitors such as, but not limited to, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline and venlafaxine,
- Suitable anti-manic and anti-psychotic agents include:
- phenothiazines such as, but not limited to, acetophenazine, acetophenazine maleate, chlorpromazine, chlorpromazine hydrochloride, fluphenazine, fluphenazine hydrochloride, fluphenazine enanthate, fluphenazine decanoate, mesoridazine, mesoridazine besylate, perphenazine, thioridazine, thioridazine hydrochloride, trifluoperazine, and trifluoperazine hydrochloride,
- phenothiazines such as, but not limited to, acetophenazine, acetophenazine maleate, chlorpromazine, chlorpromazine hydrochloride, fluphenazine, fluphenazine hydrochloride, fluphenazine enanthate, fluphenazine decanoate, mesoridazine, mesoridazine besylate, per
- thioxanthenes such as, but not limited to, chlorprothixene, thiothixene, and thiothixene hydrochloride, and
- heterocyclic drugs such as, but not limited to, carbamazepine, clozapine, droperidol, haloperidol, haloperidol, decanoate, loxapine succinate, molindone, molindone hydrochloride, olanzapine, pimozide, quetiapine, risperidone and sertindole.
- Hypnotic agents and sedatives that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, clomethiazole, ethinamate, etomidate, glutethimide, meprobamate, methyprylon, Zolpidem and barbiturates (e.g. amobarbital, apropbarbital, butabarbital, butalbital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital and thiopental).
- clomethiazole ethinamate, etomidate, glutethimide, meprobamate, methyprylon, Zolpidem and barbiturates (e.g. amobarbital, apropbarbital, butabarbital, butalbital, mephobarbital, methohexital, pentobarbital, phenobarbital
- Anxiolytics and tranquilizers that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, benzodiazepines (e.g. alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam and triazolam), buspirone, chlordiazepoxide and droperidol.
- benzodiazepines e.g. alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate
- Anticancer and antineoplastic agents that can be used to be comprised in the objects or coatings according to the method of present invention, but are not limited to, paclitaxel, docetaxel, camptothecin and its analogues and derivatives (e.g. 9-aminocamptothecin, 9- nitrocamptothecin, 10-hydroxycamptothecin, irinotecan, topotecan and 20-O- ⁇ - glucopyranosyl camptothecin), taxanes (e.g.
- baccatins cephalomannine and their derivatives
- carboplatin cisplatin
- interferon- ⁇ 2A interferon- ⁇ 2B
- interferon- ⁇ N3 interferon- ⁇ N3 and other agents of the interferon family
- levamisole altretamine
- cladribine tretinoin
- procarbazine dacarbazine, gemcitabine
- mitotane asparaginase
- porfimer mesna, amifostine
- mitotic inhibitors including podophyllotoxin derivatives such as, but not limited to, teniposide and etoposide, and vinca-alkaloids such as, but not limited to, vinorelbine, vincristine and vinblastine.
- Antihyperlipidemic or lipid-lowering or hyperlipidemic agents that can be used to be comprised in the objects or coatings according to the method of present invention, but are not limited to, HMG-CoA reductase inhibitors such as atorvastatin, simvastatin, pravastatin, lovastatin and cerivastatin, and other lipid- lowering agents such as, but not limited to, clofibrate, fenofibrate, gemfibrozil and tacrine.
- Anti-hypertensive agents that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, arnlodipine, benazepril, darodipine, dilitazem, diazoxide, doxazosin, enalapril, eposartan, losartan, valsartan, felodipine, fenoldopam, fosinopril, guanabenz, guanadrel, guanethidine, guanfacine, hydralazine, metyrosine, minoxidil, nicardipine, nifedipine, nisoldipine, phenoxybenzamine, prazosin, quinapril, reserpine and terazosin.
- Cardiovascular preparations that can be used to be comprised in the objects or coatings according to the method of present invention include, by way of example, angiotensin converting enzyme (ACE) inhibitors such as, but not limited to, enalapril, l-carboxymethyl-3-l-carboxy-3- phenyl-(lS)-propylamino-2,3,4, 5-tetrahydro-lH-(3S)-l-benzazepine-2-one, 3-(5-amino-l- carboxy-l-S-pentyl)amino-2,3,4, 5-tetrahydro-2-oxo-3-S-l-H-benza-zepine-l -acetic acid or 3-(l-ethoxycarbonyl-3-phenyl-(lS)-propylamino)-2,3,4,5-tetrahydro-2-oxo-(3S)-ben zazepine-1 -acetic acid monohydrochloride; cardiac glycosides
- Anti-viral agents that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, anti-herpes agents such as acyclovir, famciclovir, foscamet, ganciclovir, idoxuridine, sorivudine, trifluridine, valacyclovir and vidarabine; anti-retroviral agents such as didanosine, stavudine, zalcitabine, tenovovir and zidovudine; and other antiviral agents such as, but not limited to, amantadine, interferon- alpha, ribavirin and rimantadine.
- anti-herpes agents such as acyclovir, famciclovir, foscamet, ganciclovir, idoxuridine, sorivudine, trifluridine, valacyclovir and vidarabine
- anti-retroviral agents such as didanosine, sta
- estrogens e.g. ⁇ -estradiol (i.e. l,3,5-estratriene-3,17 ⁇ -diol, or 17 ⁇ -estradiol) and its esters, including estradiol benzoate, valerate, cypionate, heptanoate, decanoate, acetate and diacetate; 17 ⁇ -estradiol; ethinylestradiol (i.e.
- 17 ⁇ -ethinylestradiol and esters and ethers thereof, including ethinylestradiol-3-acetate and ethinylestradiol-3-benzoate; estriol and estriol succinate; polyestrol phosphate; estrone and its esters and derivatives, including estrone acetate, estrone sulfate, and piperazine estrone sulfate; quinestrol; mestranol; and conjugated equine estrogens.
- Androgenic agents also included within the class of sex steroids, are drugs such as the naturally-occurring androgens androsterone, androsterone acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol- 3- acetate, androstenediol- 17-acetate, androstenediol-3,17-diacetate, androstenediol-17- benzoate, androstenediol-3-acetate-17-benzoate, androstenedione, dehydroepiandrosterone (DHEA or prasterone), sodium dehydro-epiandrosterone sulfate, 4-dihydrotestosterone (DHT or stanolone), 5 ⁇ -dihydrotestosterone, dromostanolone, dromostanolone propionate, ethylestrenol, nandrolone phenpropionate,
- Muscarinic receptor agonists that can be used to be comprised in the objects or coatings according to the method of present invention include, by way of example, choline esters such as, but not limited to, acetylcholine, methacholine, carbachol, bethanechol (carbamylmethylcholine), bethanechol chloride, cholinomimetic natural alkaloids and synthetic analogues thereof, including pilocarpine, muscarine, McN- A-343 and oxotremorine.
- choline esters such as, but not limited to, acetylcholine, methacholine, carbachol, bethanechol (carbamylmethylcholine), bethanechol chloride, cholinomimetic natural alkaloids and synthetic analogues thereof, including pilocarpine, muscarine, McN- A-343 and oxotremorine.
- Muscarinic receptor antagonists that may be used in this invention include belladonna alkaloids or semi- synthetic or synthetic analogues thereof such as, but not limited to, atropine, scopolamine, homatropine, homatropine methyl bromide, ipratropium, methantheline, methscopolamine and tiotropium.
- US 5,145,684 discloses particles consisting essentially of 99.9 to 10% by weight of a crystalline drug substance having a solubility in water of less than 10 mg/ml, said drug substance having a non-crosslinked surface modifier adsorbed an the surface thereof in an amount of 0.1 to 90% by weight and sufficient to maintain an effective average particle size of less than about 400 nm.
- a modified steroid A aqueous dispersion comprising 5% steroid A, with a particle size distribution ranging from about 68 to 520 nm and a number average particle size of 204 nm.
- US 5,503,723 discloses refining a nanoparticle dispersion by placing it between two electrodes and applying an electric field between said electrodes, wherein the dispersion consists essentially of particles of poorly soluble crystalline therapeutic or diagnostic agent, wherein 99% of the particles have a particle size below 400 nm and are associated with a surface modifier which is capable of stabilizing the nanoparticles.
- the dispersion describes a danazol dispersion wherein 10% of the particles are reduced in size down to 180 nm.
- US 5,858,410 discloses a drug carrier, prepared using the jet stream principle and using surfactants such as Tween 80 and mannitol, comprising particles of a therapeutic agent which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein the therapeutic agent has an average diameter below 1,000 nm and the proportion of particles larger than 5 ⁇ m in the total population is less than 0.1%.
- aqueous nanosuspensions comprising 2-15% of a substituted pteridine and at least 0.1% Tween 80 wherein the average particle diameter is in a range from 200 to 800 nm.
- US 5,922,355 discloses preparing microparticles of a water-insoluble or poorly soluble compound by, prior to or during reducing particle size (e.g. by sonication, homogenization, milling, microfluidization and precipitation, or recrystallization and antisolvent precipitation), mixing said particles with (a) a phospholipid and (b) at least one surfactant such that the concentration of phospholipid and surface modifier in the suspension or solid form is in the range of 0.1 to 50%, and thereafter applying energy to the mixture.
- reducing particle size e.g. by sonication, homogenization, milling, microfluidization and precipitation, or recrystallization and antisolvent precipitation
- US 6,497,905 discloses converting crystalline itraconazole into its amorphous form as a solid solution of a normally hydrophobic vehicle such as glyceryl monostearate, a monoglyceride, a diglyceride, a triglyceride, or a wax.
- This solid solution may be used as a component of a granular particle wherein itraconazole is present at about 5 to 60% by dry weight. Particle size of this granular particle is not specified.
- International Patent application WO 2004/043580 discloses an emulsification method comprising flowing, conducting or circulating a pre-mix of two or more immiscible liquids, said pre-mix preferably comprising at least a hydrophilic liquid and at least a lipophilic liquid, through one or more magnetic fields under conditions to emulsify the said pre-mix.
- emulsions prepared according to this method may be included into veterinary or pharmaceutical compositions, this document does not refer to the solubilization of poorly soluble drugs as such.
- US 2007/0082054 Particle size reduction of bioactive compounds, describes a method for reducing the average size of biologically active compound solid particles or agglomerates suspended in a liquid by flowing one or more times said liquid having biologically active compound solid particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound solid particles or agglomerates by at least 25%, wherein the linear flow rate of said liquid through each said magnetic field is between 0.25 and 25 m/s.
- These methods of particle size reduction can be used to reduce the average size of the particles in suspension and to improve the deposition of the reduced size colloidal particles suspended in an aqueous medium or in an aqueous medium slurry or the reduced size particles that stabilize an emulsion under the influence of an electric field onto an electrode or porous substrate placed in front of an electrode whereby the electric fields involve unbalanced AC electric fields (UAC-EPD).
- UAC-EPD unbalanced AC electric fields
- the material selected for coating are those upon which the molecules may be deposited via electrochemical deposition under an unbalanced alternating voltage.
- Suitable materials are electrically conductive, and may include metals (e.g., aluminum, antimony, cadmium, chromium, cobalt, copper, gold, iron, lead, magnesium, mercury, nickel, palladium, platinum, silver, tin, tungsten, zinc), metal alloys (steel, brass, bronze, etc.), semiconductors (e.g., silicon, gallium or germanium semiconductor materials), and/or conductive polymers (e.g., polypyrrole).
- the electrodes used in present invention can for instance comprise conductive polymers.
- organic conductive polymers include poly(acetylene)s, poly(pyrrole)s, poly(thiophene)s, poly(aniline)s, poly(fluorene)s, poly(3-alkylthiophene)s, polytetrathiafulvalenes, polynaphthalenes, poly(p-phenylene sulfide), poly(para-phenylene vinylene)s, polyethelene terephthalate Dacron®, nylon, silk or other natural or synthetic polymeric material.
- these linear backbone polymers are known as polyacetylene, polyaniline, etc. "blacks" or "melanins”.
- the suspensions were prepared using fresh deionised water obtained from a commercial ion exchange setup (Sation Aqualab 50) and with an initial conductivity of 0.04 ⁇ S/cm.
- powder SM8-grade ⁇ -alumina (Baikowski) was chosen and a constant concentration of 200g/L was used for all experiments.
- the powder was charged by adjusting the pH below the IEP by means of nitric acid (Analytical reagent grade, 65%, Fluka) (Table T).
- the IEP itself was determined by a potentiometric titration (Matec ESA 9800) (Fig. 6) while the particle size was measured using light scattering (Malvern Mastersizer+) (Fig. T).
- each suspension was agitated 15 minutes on a magnetic stirring plate, followed by an additional 15 minutes in an ultrasonic bath (Branson 2510). Electrophoretic deposition was carried out in a teflon cell with two electrodes placed vertically at 3.5 cm distant from each other. The area available for deposition was 9 cm 2 .
- the conductive polymer (carbon doped poly oxymethylene) deposition electrode was coated with graphite (NGS Dragon Seal Graphite) before deposition.
- NGS Dragon Seal Graphite graphite
- Prior and after each experiment the temperature and conductivity (WTW inolab cond level T) of the suspension is recorded (2).
- the signal (1) was generated using a function generator (HP 3314A) and amplified with an operational amplifier (Trek PZD 700 m/s).
- EXAMPLE 1 Controllability of the process OC-AI 2 O 3 was deposited using the technology of present invention. The deposition rate of OC-AI 2 O 3 versus the symmetry of the applied signal V 1 , V 2 , t l5 1 2 (as defined in Figure 1). The suspension consisted of a 200 g/L SM8 in water containing 4.10 "4 M HNO 3 .
- symmetry of the signal was varied, by varying the height (amplitude) and width (pulse duration) of the triangular waves while maintaining a total period of 20 ms, a peak to peak height of 500 V and a net integral lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one period.
- the asymmetry factor is determined as the ratio between the pulse heights, which is equal to the ratio of the pulse widths.
- Fig. 3 shows that the deposition rate is zero when the applied field is symmetric
- conductive titanium diboride and negatively charged titanium dioxide powder were also deposited.
- the obtained deposits are of similar quality as those obtained with the non conductive positively charged alumina powder. No drying cracks were formed, which is typical for deposits with a high green density.
- the green density of the Al 2 O 3 deposits obtained by AC-EPD is 60.6 +
- AC-EPD allows the electrophoretic deposition from aqueous suspensions at high voltages.
- AC-EPD avoids the formation of gas bubbles on the electrode during electrophoresis from the electrolysis of water.
- AC-EPD allows electrophoretic deposition from aqueous instead of organic solvent suspensions, which is strongly preferred from an environmental, safety and economic perspective, while maintaining the surface quality and processing rate of DC- EPD using organic solvents.
- EXAMPLE 2 Material and Methods Fresh deionised water with an initial conductivity of 0.04 ⁇ S/cm and prepared with a commercial ion exchange setup (Sation Aqualab 50) was used for all suspensions.
- HNO 3 (Fluka 65%) was used as a charging agent for the experiments with alumina.
- a new suspension was prepared using 50 ml freshly prepared water and the indicated amount of powder and charging agent (Table 1). The suspensions were magnetically stirred for 15 minutes; followed by 15 minutes of treatment in an ultrasonic bath (Branson 2510), subsequently followed by 15 minutes of stirring on a magnetic plate.
- a programmable function generator (HP 3314A) was used to generate the unbalanced AC signal.
- a bipolar operational power supply and amplifier (Kepco BOP IOOOM or Trek PZD 700m/s) were used to amplify this by a factor of 100 or 200.
- the resulting signal with a peak to peak amplitude of 500 V and a frequency of 1 to 50 Hz, was monitored with a digital oscilloscope (Fluke 97 50MHz Scopemeter). One period of the signal is depicted in Fig. 1.
- Deposition was carried out for 1200 s in a vertical cell equipped with conductive polymer (carbon doped poly oxy methylene (POM)) or stainless steel deposition electrodes and stainless steel counter electrodes with an electrode surface of 9 cm 2 and a separation distance of 3.5 cm.
- the deposition electrode is coated with graphite prior to deposition in order to ensure easy removal of the deposit after drying.
- the deposit is formed on the electrode that is negatively, respectively positively charged during the high amplitude section of the signal for the Al 2 O 3 , respectively TiB 2 and TiO 2 powder.
- the suspension conductivity and temperature was measured before each experiment (WTW inoLab Cond Level 2 equipped with a WTW LR 325/01 probe). All deposits were visually inspected for defects, and weighed in order to determine the yield.
- White light interferometry (Wyko NT3300, Veeco) was used to measure the deposit surface roughness.
- the green density as a percentage of the theoretical density was determined using the Archimedes method with ethanol as solvent and encapsulation with a lacquer with known dry density (Enthone B. V., The Netherlands).
- the green density of SM8 samples isostatically pressed into a cylindrical shape at 300 MPa was measured to be 57.90 + 0.03%.
- Aluminium oxide is an amphoteric oxide of aluminium with the chemical formula Al 2 O 3 that can react as either an acid or base.
- suitable amphoteric oxides that are suitable for the UAC-EPD present invention are the amphoterics comprising zinc, tin, lead, aluminium, and beryllium and amphoteric oxides of most metalloids (for instance Boron (B), zirconium (Zr), Silicon (Si), Germanium (Ge), Arsenic (As), Antimony (Sb), Tellurium (Te) and Polonium (Po)) and the amino acids, proteins, sugars, fatty acids or nulceotides which have amine and carboxylic acid groups or such amino acids and protein comprised in a suspended particles or a cell or a fragment or organelle thereof for instance a prokaryote cells such as cell of the bacteria or Archaea or an eukaryote cell such as the animals, plants, fungi, and protests cells
- metalloids for instance
- organelles, cell components or macromolecules of eukaryotic cells such as chloroplast (plastid), endoplasmic reticulum, Golgi apparatus, Mitochondrion, Vacuole, Nucleus, Organelle/Macromolecule, acrosome, autophagosome, centriole, cilium, glycosome, glyoxysome, hydrogenosome, lysosome, melanosome, mitosome, myofibril, nucleolus, parenthesome, peroxisome, ribosome or vesicle which have amine and carboxylic acid groups can be deposited by UAC-EPD.
- chloroplast plastid
- endoplasmic reticulum Golgi apparatus
- Mitochondrion Vacuole
- Nucleus Organelle/Macromolecule
- acrosome autophagosome
- centriole centriole
- cilium glycosome
- glyoxysome hydrogenosome
- lysosome melanosome
- Prokaryotic organelles, cell components and macromolecules such as carboxysome, chlorosome, flagellum, magnetosome, nucleoid, plasmid, ribosome or thylakoid which have amine and carboxylic acid groups can be deposited by UAC-EPD.
- Titanium dioxide also known as titanium(IV) oxide or titania
- titanium(IV) oxide or titania is the naturally occurring oxide of titanium, chemical formula TiO 2 . It can be used as a pigment, it is then called titanium white, Pigment White 6, or CI 77891.
- Other oxides suitable for the UAC- EPD of present invention are titanium oxides in titanium alloyed with iron, aluminium, vanadium, molybdenum.
- the green density is a value that relates to the particle packing in the formed object, and therefore is often used as a measure of the quality of the formed object. This value is traditionally stated as a percentage of the theoretical density of the material.
- the mass of the object is recorded.
- the object is coated with a lacquer that seals off this porosity, and after drying the mass of the coated object is registered as well.
- the volume of the coated object is measured by submerging it in a solvent of known density and measuring the buoyancy.
- the Archimedes principle is used to calculate the total volume of the coated object. From the weight difference before and after coating, the volume of the lacquer can be calculated and subtracted from the total volume.
- the density of the sealing lacquer is determined previously by coating a substrate of known weight and density followed by measuring the volume of coating using the Archimedes method. Powder particle information:
- SM8 grade alumina depicts a mono modal particle size distribution.
- the SM8 powder has an irregular morphology which is closer to spherical particles than to platelets or needles.
- Influence of frequency and amplitude 50 Hz is the maximum attainable frequency with a HP 3314A function generator for a programmed signal while maintaining sufficient resolution. Deposits were also made with 20, 5 and 1 Hz signals (Fig 8). The yield increases as the frequency increases but starts to level off above about 20 Hz. The reproducibility of the yield data is highest at 50 Hz. Hence this frequency was chosen for most experiments. At 1 Hz, the deposits were so thin that they warped during drying and cracked under their own weight. Despite of this, the deposits remain free of gas bubbles even at frequencies as low as 1 Hz and the high green density is maintained.
- the field strength is increased to improve the deposition rate.
- too strong fields are known to yield unstable systems resulting in lower surface quality deposits.
- the amplitude was increased to 750Vp-p during AC-EPD.
- the deposit yield decreased to 0.569g over 40 minutes while employing this stronger field.
- the only explanation that can be offered is that the inverse field strength increases with the amplitude, causing resuspension of a larger fraction of the deposited particles reducing the overall deposition rate.
- a second but more obvious disadvantage of the higher applied voltage is that the current increases proportionally. The higher current leads to an increased temperature, which is detrimental for the deposition rate and deposit quality.
- DC-EPD from ethanol suspensions typically shows a self-limiting behavior when working under constant voltage conditions (Anne, G., et al. Journal of the American Ceramic Society 89, 823-828 (2006)).
- the possible reason for this behavior is the presence of thick double layers in the still porous deposit which hamper the free flow of ions. Since double layers are typically thinner in aqueous environment, the self-limiting behavior is unlikely to occur in water. Instead, the deposition rate remains constant and the yield increases linearly with time (Fig. 8), suggesting the possibility of an unlimited deposit thickness.
- Joule heat losses occurring in the suspension system are one of the main practical concerns when performing electrophoretic deposition, causing unstable suspensions and/or deposits of inferior quality.
- a 50 Hz 500 Vp-p signal was applied for 20 minutes and a deposit was formed.
- 200 g/L SM8-ethanol suspensions were prepared. The conductivity of the ethanol suspensions was brought to 25 ⁇ S/cm using 0.1N HN03 in ethanol. One suspension was subjected to 200 V DC while the other was deposited using the same unbalanced field as the aqueous suspension.
- the temperature of all systems decreases as a function of time.
- the initial temperature of the suspensions is above room temperature due to the ultrasonification needed to disperse the particles. Because less heat is generated in the system than transported to the environment, the temperature gradually decreases.
- the slower reduction in temperature of the aqueous system is either due to a higher Joule heat generation in the suspension or a slower transport of heat to the environment.
- UAC-EPD can be used to form deposits from emulsions stabilized by charged solid particles.
- a 0.5 M propionic acid solution (Analytical reagent grade, Prolabo), and a 0.1 M nitric acid solution (Analytical reagent grade, 65%, Fluka) were used as charging agent as indicated in Table 4.
- the cyclohexane is added to the suspension containing the propionic acid and vigorously mixed for 30 minutes using a small size lab mixer (Lab egg, Ika). The size of the droplets is measured en shown in Fig. 14. After this the second suspension is added to the emulsion and gently stirred to homogenise the suspension / emulsion mixture. The powder in this second suspension is intended to co-deposit with the droplets in order to form a solid structure in between the deposited cyclohexane. These mixtures are then placed in the cell used for electrophoretic deposition.
- the EPD experiments were carried out in a cell with vertically placed electrodes with a separation distance of 3.5 cm and an effective area of 9 cm 2 .
- the deposition electrode consists of a conductive polymer plate (carbon doped polyoxymethylene (POM)), while stainless steel is used as counter electrode.
- POM carbon doped polyoxymethylene
- the polymer electrode Prior to EPD, the polymer electrode was dip- coated with graphite (Dragon Seal Graphite, NGS) in order to ensure easy removal of the deposit.
- the emulsion / suspension system was recirculated using a peristaltic pump (Watson-Marlow 505 Du) Electrophoretic deposition was performed using an unbalanced alternating signal with a frequency of 50 Hz and an amplitude of 500 V p _ p (Fig. 15b).
- This signal was applied using a function generator (HP 3314A) combined with an operational amplifier (Trek PZD 700 m/s). EPD was carried out during 20 minutes. The deposits were dried at room temperature for 24 hours. The yield was recorded by weighing the electrode prior to deposition and after drying. Finally, the deposits were consolidated by pressureless sintering in air at 1400 0 C for 30 minutes, with a heating and cooling rate of 10°C/min (Nabertherm HT16/17).
- the present invention thus concerns the use of UAC-EPD to form deposits from emulsions stabilized by charged solid particles.
- the solid particle emulsions are obtainable by mixing at least two immiscible liquids to which solid particles or grains are added.
- Control experiment performed using an absolute ethanol (Prolabo) based suspension and DC source. For this experiment a voltage of 200V was applied.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Metallurgy (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Devices For Indicating Variable Information By Combining Individual Elements (AREA)
Abstract
From an environmental, safety and economic perspective water should be the solvent of choice for electrophoretic deposition under industrial circumstances. However, because of the electrolytic decomposition of water, the majority of EPD is carried out in non-aqueous solvents. Approaches of the art for aqueous deposition involve the separation of the reaction and deposition front by means of a membrane, the use of palladium electrodes to absorb the formed hydrogen, addition of chemicals to suppress the electrolysis reaction, or lowering voltages below the threshold for water electrolysis. With the first two solutions, the production of coatings is impractical since the deposit is not formed on the electrode, or the electrode material is not suitable since the substrate is usually prescribed by the application. The use of specialty chemicals is expensive and difficult to control. Low voltages have been used to form high quality deposits from aqueous systems but they display very low deposition rates, which are not attractive from an economical perspective. Present invention provides a system and a means for which high voltages can be used in the electrophoretic deposition from aqueous suspensions without decomposition of water at satisfying deposition rates. It shows that the deposits obtained show a high green density with excellent surface quality.
Description
AQUEOUS ELECTROPHORETIC DEPOSITION
Technical field of the invention
The present invention relates generally to the process of the deposition of 1) colloidal particles suspended in an aqueous medium or in an aqueous medium slurry or 2) organic or metallo-organic molecules dissolved in an aqueous medium, (preferably concentrated systems and most preferably highly concentrated systems) under the influence of an electric field onto an electrode or porous substrate placed in front of an electrode.
More particularly the present invention relates to a controllable system and method for electrophoretic deposition in unbalanced AC electric fields (UAC-EPD) to form smooth deposits with no visible defects or to form a coating or a deposit.
Background of the invention:
Electrophoretic deposition (EPD) is a colloidal processing technique in which a suspension or solution of charged particles or charged organic or metallo-organic molecules is placed in an electric field. The charged particles move towards one of the electrodes (electrophoresis) and subsequently form a deposit on this electrode (deposition) see VanderBiest, O. & Vandeperre, L. J. Electrophoretic deposition of materials. Annual reviews of material science 29, 327-352 (1999). From environmental, economical and technical point of view water is the ideal solvent. Since water covers 2/3 of the earth's surface and its is involved in all biological processes in living cells and life on earth dependents on it; it is an ideal solvent for many natural molecules. Molecules that are charged or partially charged dissolve readily in water while molecules that do not have charges or partial charges on their surface do not mix readily with water. Demineralised water is non-toxic and can be produced at low cost in vast quantities. However these are not the most important advantages that water has to offer if we look at aqueous EPD from a technical point of view. Water has a higher dielectric constant than all of the other common solvents. This leads to higher an electrophoretic mobility, μ (m2/Vs), and zeta potential. Since according to the basic principle of EPD, Hamaker's law (formula 2), the yield, Y (g), is proportional to this electrophoretic mobility, water has the potential of delivering higher yields for the same applied electric field, E (V/m), electrode area, S (m2) and suspension solids concentration, Cs (g/m3), than any other solvent.
Y = J μ E S Cs dt. (2) ti
In addition water is the basic protonic solvent. The higher degree of dissociation ensures a more efficient charging of all pH sensitive particle surface groups and hence adds to the higher mobility in water at a given acid concentration. A final less obvious advantage of aqueous suspensions is the vast amount of knowledge on the behaviour of particles in aqueous media. Since water based systems are preferred in production environment most additives, such as binders and dispersants, have been optimized for water. Water would therefore be the solvent of choice for electrophoretic deposition, but for the electrolytic decomposition of water. Most EPD is therefore carried out in non-aqueous solvents, direct current electrophoretic deposition from water being limited to low electric fields. Since the deposition rate depends directly on the strength of the applied, direct current EPD from water at low field is not attractive from an economical perspective. However, aqueous deposition has been studied by numerous researches and some solutions for the electrolysis problem have been published. J. Tabellion et al. in Materials Science volume 39, pages 803-811 (2004) proposed separating the reaction and deposition fronts; by means of a membrane; T. Uchikoski et al. in Journal of Materials Research volume 16, pages 321-324 (2001) proposed the use of palladium electrodes to absorb the hydrogen formed; Sakurada in Journal of the Ceramic Society of Japan volume 112, pages 156-155 (2004) proposed the addition of chemicals to suppress the electrolysis reaction; and R.C. Hayward et al. in Nature, volume 404, pages 56-59 (2000) and M. Bohmer in Langmuir, volume 12, pages 5747-5750 (1996) proposed lowering the voltages below the threshold for water electrolysis. With the first two solutions, the production of coatings is impractical because the deposit is not formed on the electrode, or the expensive electrode material is not suitable or economically infeasible as substrate material. The use of specialty chemicals is expensive, difficult to control and not ecological. R.C. Hayward et al. and M Bohmer have reported high quality deposits from aqueous systems at low voltages. However, despite the high quality of the deposits claimed using these techniques they display low deposition rates (e.g. 30 minutes to form a mono-layer). Y. Hirata et al. in Journal of the Ceramic Society of Japan, volume 99, 108-113 (1991) reported the use of symmetric AC signals to form deposits by EPD from aqueous suspensions at high
frequencies, but the deposition rate was extremely low and seemed to be controlled by the diffusion of alumina in the suspension.
WO 2004/052489A describes a method of attaching a nanostructure-containing material onto a sharp tip of an object, the method comprising: (i) forming a suspension of nanostructure-containing material in a liquid medium; (ii) immersing at least one electrode in the suspension; (iii) placing the sharp tip into the suspension; and (iv) applying a direct or alternating current to the immersed electrode and the sharp tip causing at least a portion of the nanostructure-containing material in the suspension to become attached to the object proximate at apex of the sharp tip. WO 2004/052489A discloses a dielectrophoresis method.
JP 52-056143A describes alternating current electrodeposition coating using an aqueous paint containing a salt of a purified polycarboxylic acid resin as binder.
DD 215338 Al describes electrophoretic precipitation from a suspension using asymmetrical alternating voltage in which the negative portion is 1 to 25% of the maximum value of the positive voltage (by superimposing DC signal onto an AC signal) to improve coating e.g. of ceramic moulds. As a result unwanted electrochemical reactions were slowed down, yet not fully stopped. DD 215338A1 reported that the electrochemical dissolution of the electrodes was reduced
GB 253091A describes a method of depositing- organic material electrically on or in a fabric which comprises placing the fabric on the outer surface of a gas-permeable anode in contact with an aqueous electroconducting emulsion of the organic material to be deposited, passing a depositing current through the emulsion and the anode and withdrawing the gas formed at the outer surface of the anode through the anode by causing a lower pressure to be exerted on its inner surface than on its outer surface. GB 253091A further stated that the current should preferably be an effectively unidirectional one, it may be a current of constant value, or a direct current of pulsating character and in some instances it is useful to employ an unbalanced alternating current, which is most conveniently obtained by superimposing an alternating current upon a direct current. US 1,589,327 describes a process of depositing a cellulosic compound on an electroconducting surface of an object, which comprises the steps of bringing said surface into contact with an electroconducting emulsion containing droplets of the cellulosic compound and passing a depositing electric current through said surface and emulsion. US
1589327 further describes that for some purposes it may be convenient to employ a considerably unbalanced alternating current.
Thus, there is an urgent need in the art for EPD systems that allow the use of high voltage with high deposition rates in an aqueous (watery) medium and in particular of EPD systems with further reduced or completely halted gas bubble generation due to water electrolysis.
Summary of the invention
The present invention concerns an electrophoretic deposition (EPD) process in reduced or limited water electrolysis in an aqueous environment characterized in that the process involves subjecting positively or negatively charged or partially charged molecules or colloidal particles to an unbalanced alternating current (UAC) electric fields for depositing molecules or particles in aqueous medium from the aqueous medium onto an electrode or porous substrate placed in front of an electrode. The controllable system and method for electrophoretic deposition in unbalanced AC electric fields (UAC-EPD) of present invention surprisingly allows the deposition of thin layers with an average thickness in the nanometer scale but also thick layers with an average thickness in the centimeter, millimeter or micrometer scale.
It is an object of present invention to deposit cationic polymers in smooth coatings from an aqueous medium onto anodes or porous substrate placed in front of an anode by subjecting them to unbalanced (asymmetric) alternating current (UAC) electric signals to reduce or prevent electrolysis of water in the aqueous medium.
It is also an object of present invention to deposit anionic polymers in smooth coatings from an aqueous medium onto cathodes or porous substrate placed in front of a cathode by subjecting them to unbalanced alternating current (UAC) electric signals to reduce or prevent electrolysis of water in the aqueous medium.
It is also an object of present invention to deposit charged microorganism and living cells or cell components in smooth coatings from an aqueous medium onto a conductive medium or electrode or porous substrate placed in front of an electrode by subjecting them to unbalanced alternating current (UAC) electric signals in which the amplitude differs significantly for the positive and negative part to reduce or prevent electrolysis of water in the aqueous medium.
It is also an object of present invention to deposited bioactive agents in thin coatings (nanometer scale average thickness) or in thick coatings (micrometer scale average thickness) from an aqueous medium onto a conductive medium or electrode or porous substrate placed in front of an electrode by subjecting them to unbalanced alternating current (UAC) electric to reduce or prevent electrolysis of water in the aqueous medium.
The present invention further concerns a system of high voltage EPD of colloidal particles suspended in an aqueous medium while the decomposition of water is suppressed below the point of gas bubble formation. The current problem in the art of high voltages water decomposition is solved by applying an unbalanced alternating electric field. Contrary to what one might expect, the particles form an adhering deposit on the selected electrodes (deposition electrodes), the experimental results of present invention clearly demonstrated that by present invention deposits with high green density (> 60 % in the case of monomodal spherical submicron Alumina particles) and smooth surface can be formed from aqueous suspensions. These findings allow the replacement of volatile, expensive and environmentally unfriendly solvents (as currently used in the art) by an aqueous (watery) medium while a strong enough electric field can be applied in order to ensure a satisfying deposition rate. The overall yield is lower than we are accustomed from DC-EPD. On the other hand only a fraction of the time is used to deposit particles. Taking that into account, the yield in function of deposition time is larger than during DC-EPD.
Defect-free high density green deposits can be obtained from aqueous suspensions if the electrolysis of water is avoided. The quality of these deposits is equal or better than those produced in the past by conventional electrophoretic deposition from alcohol based suspensions. Furthermore the deposition mechanics still exhibit a linear increase of deposit yield and no self limiting behaviour was observed, suggesting the possibility of limitless thickness.
In accordance with the purpose of the invention, as embodied and broadly described herein, the invention is broadly drawn to an unbalanced AC electric fields (UAC-EPD) process for depositing amphoteric substance or self-charging compounds in aqueous solutions under the influence of an unbalanced AC electric field onto an electrode or porous substrate placed in front of an electrode or for depositing colloidal particles with an electric charge or that comprise charged metallo-organic molecules dissolved or suspended in an aqueous medium or an aqueous slurry. UAC-EPD is preferably carried out using
concentrated systems and most preferably using highly concentrated systems. In diluted solutes or suspended systems, the particles can move independently from one another. In other words if one solute or particle moves due to the electric field it should not be influenced in its movement due to the presence of other particles or solutes. In concentrated suspensions or solutions individual particles or solutes experience influence from each other during movement. In highly concentrated systems the hydrodynamic diameters of the components, being either particles or solutes, overlap. The present invention is particularly suitable for molecules that readily mix in water as a suspension or a solution. In one aspect of the invention, the electrophoretic deposition (EPD) process for depositing charged, partially charged or self-charging compounds or organic or metallo- organic molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to unbalanced alternating current (UAC) electric fields. These charged or self- charging compounds or molecules are solved in the aqueous medium or these charged or self-charging compounds or molecules are in colloidal particles. The charged or self- charging compounds or molecules can be in cells, cell organelles or cell components.
Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged metallo-organic molecules dissolved or suspended in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to an unbalanced AC- signal that has a voltage evolution of which the positive and negative amplitude differ in absolute value
Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to an AC-signal of which the shape of the negative and positive signal part differ, preferably in amplitude and most preferably in both amplitude and duration and whereof the net resulting DC-signal of said unbalanced signal, obtained by calculating the voltage average over one period, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged metallo-organic molecules dissolved or suspended in
aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to a signal in which the amplitude differs significantly for the positive and negative part, while maintaining a net integral over one period of lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to an UAC fields as depicted in figure 1.
Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to an unbalanced AC electric fields of one symmetrical sinus waves on top of another symmetrical sinus wave with an integral of lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one time period
Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to AC-fields that have an unbalanced form, yet yielding no net DC signal.
Yet another embodiment of present invention is an electrophoretic deposition (EPD) process for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode involves subjecting the molecules or colloidal particles to unbalanced AC electric fields that are composed of signals with different amplitudes for the negative and the positive part but with an integral of lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one time period. It can be AC fields in which the amplitude and the duration of the negative and the positive part differ, but the overall integral over one period is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
In still another aspect of the invention, unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention as described above is used to coat or paint a device or instrument for instance to coat a medical prostheses, an orthopaedic implant, dental endodontic or dental implant. Another aspect of the invention is the use of unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention to remove said charged or self-charging compounds or molecules form an aqueous medium.
In a particular embodiment of present invention the unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention to produce a strong lightweight metals and alloys.
In yet another particular embodiment of present invention the unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention to produce a food or a feed.
Another aspect of the invention is the use of asymmetric alternating current electrophoretic deposition (UAC- EPD) of present invention to form smooth deposits with no visible defects or the use of asymmetric alternating current electrophoretic deposition (UAC- EPD) of any of present to form deposits with a smooth surface of a Ra of 10 to 50 μm, preferably a Ra of 10 to 10000 nm, more preferably a Ra of 10 to 500 nm, and most preferably a Ra of 10 -200 nm. A further aspect is the realisation of a deposit with high green density > 30 %, preferably a deposit with high green density > 50 % or most preferably a deposit with high green density > 60 % produced by such process.
In still another aspect of the invention, unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention as described above is used to produce a device or instrument for instance to produce a medical prostheses, an orthopaedic implant, dental endodontic or dental implant.
Aspects of the present invention are realized by a coating process comprising the steps of: immersing an electrode or porous substrate placed in front of an electrode in an aqueous medium comprising charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles and subjecting said charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles in an aqueous medium to (asymmetric) unbalanced alternating current (UAC) electric fields, having a frequency and a positive and negative part each having an amplitude and a duration, to deposit electrophoretically said charged, partially charged or self-charging
organic or metallo-organic molecules or colloidal particles onto said electrode or porous substrate placed in front of an electrode, characterised in that said amplitude of said unbalanced alternating current (UAC) electric field differs significantly for the positive and negative part, while maintaining a net integral of the applied signal over one period, i.e. average potential, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero. An electrical field must be realised between the counter electrode and the electrode in the aqueous medium comprising charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles for electrophoretic deposition to occur. This can also be realised with the counter electrode outside the vessel containing the aqueous medium, if an electric field can still be realised between the counter electrode and the electrode in the medium.
Further aspects of the present invention are realized by the use of the above- mentioned coating process to form smooth deposits with no visible defects having a surface with a Ra of 10 to 50 μm, preferably a Ra of 10 to 10000 nm, more preferably a Ra of 10 to 500 nm, and most preferably a Ra of 10-200 nm.
Aspects of the present invention are also realized by a system for electrocoating a conductive substrate with organic or metallo-organic molecules or particles in which said system coats said conductive substrate with at least one layer or coating at a controllable average thickness in the nm or in the μm scale from a suspension in an aqueous working medium of one or more types of said organic or metallo-organic molecules or particles, wherein said system comprises a power supply connected to a signal generator to generate between a counter electrode and said conductive substrate, an unbalanced alternating current (AC) signal, said signal having a frequency and a positive and negative part each having an amplitude and a duration, in which said amplitudes for said positive and negative parts differ significantly, while maintaining a net integral of the applied voltage over one period, i.e. average potential, lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, and furthermore said system comprises a control system connected to said signal generator for determining the frequency and amplitude of said unbalanced AC signal. Particular and preferred aspects of the invention are set out in the accompanying independent and dependent claims. Features from the dependent claims may be combined with features of the independent claims and with features of other dependent claims as appropriate and not merely as explicitly set out in the claims.
Although there has been constant improvement, change and evolution of devices in this field, the present concepts are believed to represent substantial new and novel improvements, including departures from prior practices, resulting in the provision of more efficient, stable and reliable devices of this nature. The above and other characteristics, features and advantages of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention. This description is given for the sake of example only, without limiting the scope of the invention. The reference figures quoted below refer to the attached drawings.
Brief description of the drawings
The present invention will become more fully understood from the detailed description given herein below and the accompanying drawings which are given by way of illustration only, and thus are not limitative of the present invention, and wherein:
Fig. 1 is a schematic view showing one period of the applied unbalanced AC signal V is the voltage and t, the time. Fig. 2 demonstrates OC-AI2O3 Deposits formed using (a) 100 V DC for 1200 s or (b) a 50
Hz unbalanced AC field with Vx= 100 V, V2= -400V, ti= 16 ms, t2= 4 ms Fig. 3: is a schematic view of the deposition rate, D, of OC-AI2O3 versus the asymmetry factor, A, of the applied signal. V1, V2, tl5 12 are defined in Figure 1. The suspension consisted of a 200 g/L SM8 in water containing 4.10-4 M HNO3. Fig. 4: demonstrates the particle size distribution of SM8 powder measured by light scattering (Mastersizer micro+, Malvern) as volume, v, versus particle diameter, d. Fig. 5: is a micrograph of SM8 α- Al2O3 powder
Fig. 6: demonstrates the electrophoretic mobility, E, of SM8 alumina as a function of operational pH for different solvent combinations: water (dashes), ethanol with 5 vol.
% water (dots) and ethanol (full line)
Fig. 7: shows the deposition of polystyrene particles from an isopropanol suspension in a 50 Hz unbalanced AC-field with an asymmetry factor of 4.
Fig. 8: demonstrates the dependence of the deposition yield, Y, upon frequency, f, and time, t, for a 200 g/L Al2O3 (SM8, Baikowski) suspension containing 4 10"4M HNO3 in an unbalanced 500 V peak to peak field with an asymmetry factor of 4. Each
experiment was repeated 3 times. The diamonds represent the time dependence at 50 Hz and the dots represent the frequency dependence after 40 minutes.
Fig. 9: displays the temperature, T, as a function of time, t, during electrophoretic deposition for AC-EPD in water (dashes), AC-EPD in ethanol (full line) and DC- EPD in ethanol (dots).
Fig. 10: provides a picture of the surface roughness of a deposit prepared by electrophoretic deposition of a 200 g/L SM8 ethanol suspension with 1 10"3 M HNO3 and deposited at 200 V DC for 20 minutes
Fig. 11: provides a picture of the surface roughness of a deposit prepared by electrophoretic deposition of a 200 g/L SM8 Water suspension with 4 10"4 M HNO3 and deposited at 50 Hz 500 Vp-p for 20 minutes.
Fig. 12: Example of an applied signal as measured during deposition (Fluke 97 scopemeter equipped with a voltage divider with a division factor of 100).
Fig. 13: Example of α-alumina (SM8 grade, Baikowski) deposit made using the signal as shown in Fig. 12.
Fig. 14: provides the droplet size distribution as volume fraction, vf, versus droplet diameter, dD, as measured using light scattering after 30 minutes stirring. All measured systems were prepared using 40 ml of aqueous suspension and 40 ml of cyclohexane, while the mass of stabilizing powder and the volume of charging agent (0.5M propionic acid) was varied: O.lg SM8/0.05 ml propionic acid (grey dashes with 2 peaks), 0.5g SM8/0.1 ml propionic acid (black dashes with 2 peaks), Ig
SM8/0.1 ml propionic acid (grey line with a single peak), 2g SM8/0.1 ml propionic acid (black line with a single peak), 5g SM8/0.2 ml propionic acid (grey dash dot with a single peak) and 1Og SM8/0.4 ml propionic acid(black dash dot with a single peak) .
Fig. 15: Schematic representation of a) the EPD cell in which 1 is a deposition electrode, 2 is a pump and 3 is a suspension and emulsion reservoir and b) the applied unbalanced AC signal as a function of voltage, V, upon time, t, with an amplitude of 500 Vp-p and a frequency of 50 Hz. Fig. 16: Micrographs of polished cross-sections of Alumina grades A (a), B (b), C(c) and E (d) after sintering (see Table 1 and 2)
Fig. 17: Solid particle stabilized emulsion droplet, where LAis liquid A, LB is liquid B, 4 is the inter-phase and P is a solid particle.
Fig. 18: Typical example of an unbalanced AC-signal generated by a function generator as voltage, V, versus time, t, in ms. The ratios V2/V1 and tl/t2 are equal to ensure the elimination of a net DC- signal.
Fig. 19: Unbalanced AC-signal as voltage, V, versus time, t, composed from two symmetrical sinus waves shifted 90° in phase and with a frequency ratio of 2.
Detailed description of the invention
The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes. The dimensions and the relative dimensions do not correspond to actual reductions to practice of the invention.
Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequence, either temporally, spatially, in ranking or in any other manner. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other sequences than described or illustrated herein. Moreover, the terms top, bottom, over, under and the like in the description and the claims are used for descriptive purposes and not necessarily for describing relative positions. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the invention described herein are capable of operation in other orientations than described or illustrated herein. It is to be noticed that the term "comprising", used in the claims, should not be interpreted as being restricted to the means listed thereafter; it does not exclude other elements or steps. It is thus to be interpreted as specifying the presence of the stated features, integers, steps or components as referred to, but does not preclude the presence or addition of one or more other features, integers, steps or components, or groups thereof. Thus, the scope of the expression "a device comprising means A and B" should not be limited to devices consisting only of components A and B. It means that with respect to the present invention, the only relevant components of the device are A and B.
Similarly, it is to be noticed that the term "coupled", also used in the claims, should not be interpreted as being restricted to direct connections only. The terms "coupled" and "connected", along with their derivatives, may be used. It should be understood that these terms are not intended as synonyms for each other. Thus, the scope of the expression "a device A coupled to a device B" should not be limited to devices or systems wherein an output of device A is directly connected to an input of device B. It means that there exists a path between an output of A and an input of B which may be a path including other devices or means. "Coupled" may mean that two or more elements are either in direct physical or electrical contact, or that two or more elements are not in direct contact with each other but yet still co-operate or interact with each other.
Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to one of ordinary skill in the art from this disclosure, in one or more embodiments.
Similarly it should be appreciated that in the description of exemplary embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects. This method of disclosure, however, is not to be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment. Thus, the claims following the detailed description are hereby expressly incorporated into this detailed description, with each claim standing on its own as a separate embodiment of this invention.
Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention, and form different embodiments, as would be understood by those in the art. For example, in the following claims, any of the claimed embodiments can be used in any combination.
Furthermore, some of the embodiments are described herein as a method or combination of elements of a method that can be implemented by a processor of a computer system or by other means of carrying out the function. Thus, a processor with the necessary instructions for carrying out such a method or element of a method forms a means for carrying out the method or element of a method. Furthermore, an element described herein of an apparatus embodiment is an example of a means for carrying out the function performed by the element for the purpose of carrying out the invention.
In the description provided herein, numerous specific details are set forth. However, it is understood that embodiments of the invention may be practiced without these specific details. In other instances, well-known methods, structures and techniques have not been shown in detail in order not to obscure an understanding of this description.
The following detailed description of the invention refers to the accompanying drawings. The same reference numbers in different drawings identify the same or similar elements. Also, the following detailed description does not limit the invention. Instead, the scope of the invention is defined by the appended claims and equivalents thereof.
Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
The following terms are provided solely to aid in the understanding of the invention.
Definitions
A molecule in the meaning of this invention is sufficiently stable group of at least two atoms in a definite arrangement held together by very strong chemical bonds, comprising the charged or self-charging molecules and the charged organic molecules and biomolecules.
The term "bio-active agent" as used herein broadly includes any compound, composition of matter, or mixture thereof, that has biological activity and can be delivered in the subject, preferably a mammal, to whom it is administered.
A biomolecule is any organic molecule that is produced by living organisms, including large polymeric molecules such as proteins, polysaccharides, and nucleic acids as well as small molecules such as primary metabolites, secondary metabolites, and natural products. As organic molecules, biomolecules comprise primarily carbon and hydrogen, nitrogen, and oxygen, and, to a smaller extent, phosphorus and sulphur. Other elements sometimes are incorporated but are much less common. Typical biomolecules are of the group of the nucleosides and nucleotides, the saccharides, lignin, lipids, amino acids, protein structures (for vitamins. A diverse range of biomolecules exist, including: small molecules (lipid, phospholipids, glycolipid, sterol, vitamin, hormone, neurotransmitter, carbohydrate, sugar, disaccharide) monomers (amino acids, nucleotides, monosaccharides), polymers (peptides, oligopeptides, polypeptides, proteins, nucleic acids, i.e. DNA, RNA oligosaccharides, polysaccharides (including cellulose) and lignin.
Nucleosides are molecules formed by attaching a nucleobase to a ribose ring. Examples of these include cytidine, uridine, adenosine, guanosine, thymidine and inosine. Nucleosides can be phosphorylated by specific kinases in the cell, producing nucleotides, which are the molecular building blocks of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). DNA or RNA has a negative charge.
Monosaccharides are the simplest form of carbohydrates with only one simple sugar. They essentially contain an aldehyde or ketone group in their structure. Examples of monosaccharide are the hexoses glucose, fructose, and galactose and pentoses, ribose, and deoxyribose Disaccharides are formed when two monosaccharides, or two single simple sugars, form a bond with removal of water. Examples of disaccharides include sucrose, maltose, and lactose.
Polysaccharides are polymerized monosaccharides, complex, carbohydrates. They have multiple simple sugars. Examples are starch, cellulose, and glycogen. They are generally large and often have a complex branched connectivity. Shorter polysaccharides, with 2 - 10 monomers, are called oligosaccharides. Lignin is a random polymer composed mainly of aromatic rings with short (up to three) aliphatic carbons chains connecting the rings. Lignin is the second most common biopolymer (after cellulose) and is one of the primary structural components of most plants. It contains subunits derived from p-
coumaryl alcohol, coniferyl alcohol, and sinapyl alcohol and is unusual among biomolecules in that it is racemic i.e. it is not optically active. The lack of optical activity is because the polymerization of lignin occurs via free radical coupling reactions in which there is no preference for either configuration at a chiral center. Lipids are chiefly fatty acid esters, and are the basic building blocks of biological membranes. Another biological role is energy storage (e.g., triglycerides). Most lipids consist of a polar or hydrophilic head (typically glycerol) and one to three nonpolar or hydrophobic fatty acid tails, and therefore they are amphiphilic. For lipids present in biological membranes, the hydrophilic head is from one of three classes: Glycolipids, whose heads contain an oligosaccharide with 1-15 saccharide residues; Phospholipids, whose heads contain a positively charged group that is linked to the tail by a negatively charged phosphate group; and Sterols, whose heads contain a planar steroid ring, for example, cholesterol. Other lipids include prostaglandins and leukotrienes which are both 20-carbon fatty acyl units synthesized from arachidonic acid. They are also known as fatty acids
Fatty acids consist of unbranched chains of carbon atoms that are connected by single bonds alone (saturated fatty acids) or by both single and double bonds (unsaturated fatty acids). The chains are usually 14-24 carbon groups long, but it is always an even number. Amino acids contain both amino and carboxylic acid functional groups. (In biochemistry, the term amino acid is used when referring to those amino acids in which the amino and carboxylate functionalities are attached to the same carbon, plus proline which is not actually an amino acid). Amino acids are the building blocks of long polymer chains. With 2-10 amino acids such chains are called peptides, with 10-100 they are often called polypeptides, and longer chains are known as proteins. These protein structures have many structural and enzymatic roles in organisms. There are twenty amino acids that are encoded by the standard genetic code, but there are more than 500 natural amino acids. When amino acids other than the set of twenty are observed in proteins, this is usually the result of modification after translation (protein synthesis). Only two amino acids other than the standard twenty are known to be incorporated into proteins during translation, in certain organisms: Selenocysteine is incorporated into some proteins at a UGA codon, which is normally a stop codon. Pyrrolysine is incorporated into some proteins at a UAG codon. For instance, in some methanogens in enzymes that are used to produce methane. Besides
those used in protein synthesis, other biologically important amino acids include carnitine (used in lipid transport within a cell), ornithine, GABA and taurine. The particular series of amino acids that form a protein is known as that protein's primary structure. This sequence is determined by the genetic makeup of the individual. Proteins have several well- classified elements of local structure formed by intermolecular attraction, which forms the secondary structure of protein. They are broadly divided in two, alpha helix and beta sheet, also called beta pleated sheets. Alpha helices are formed of coiling of protein due to attraction between the amine group of one amino acid with the carboxylic acid group of another amino acid. The coil contains about 3.6 amino acids per turn and the alkyl group of amino acid lie outside the plane of coil. Beta pleated sheets are formed by strong continuous hydrogen bond over the length of protein chain. Bonding may be parallel or antiparallel in nature. Structurally, natural silk is formed of beta pleated sheets. Usually, a protein is formed by action of both these structures in variable ratios. Coiling may also be random. The overall 3D structure of a protein is termed its tertiary structure. It is formed as result of various forces like hydrogen bonding, disulphide bridges, hydrophobic interactions, hydrophilic interactions, van der Waals force etc. When two or more different polypeptide chains cluster to form a protein, quaternary structure of protein is formed. Quarternary structure is a unique attribute of polymeric and heteromeric proteins like haemoglobin, which consists of two alpha and two beta peptide chains. A vitamin is a compound that is generally not synthesized by a given organism but is nonetheless vital to its survival or health. These compounds must be absorbed, or eaten, but typically only in trace quantities.
Coating process using unbalanced (asymmetric) AC-electrophoretic deposition
(UAC-EPD)
In theory water starts to decompose electrochemically at voltages above 1.24V [/. P. Hoare: The electrochemistry of oxygen (John Wiley & Sons Inc., New York 1968) or B. E. Conway: Electrochemical data (Elsevier publishing company, Amsterdam 1952)] However, surprisingly, in practice often potentials of 3-4V are needed before gas bubbles are formed. Nevertheless in most traditional EPD setups as well as in our experiments voltages are used that surpass this threshold more than a few times. Hence only the kinetics of the electrochemical system can be used to prevent electrolysis. This means that there must be a lower limit to the frequency above which no electrolysis occurs. In order to
determine this lower limit the influence of frequency on the deposit quality and yield was measured (Fig. 8).
Though the yield decreased appreciably at IHz no bubble formation could be observed and the deposits were defect free. This does not mean that there is absolutely no electrolysis of water at this frequency, but that at least the reaction is slow enough to prevent the nucleation of bubbles. Next to the increase in yield the higher reproducibility of the experiments at higher frequencies was striking. Hence 50Hz was chosen as the frequency to be used for all other tests.
In the past a decrease in deposition rate as the deposit grows has been noted in some systems. This behaviour was distinctively present when depositing from acidic ethanol suspensions. While this self limiting behaviour is unwished- for when producing thick deposits it can be useful if thin coatings are needed since it levels out the deposition rate over an entire electrode, no matter what the geometry is. This tendency to form layers of uniform thickness has been dubbed throwing power. The self limiting behaviour has been linked to the flow of ions trough the deposit. Either the build up of double layers in the deposit pores when using acidic ethanol systems or a depletion layer near the electrode hampers the free passage of ions. The result for both proposed mechanisms is an increased total cell resistance.
Because of the similarity between aqueous and ethanol based suspensions a second series of experiments was performed in which the deposit yield in function of time was recorded. These experiments showed that the yield increased linearly in function of time (which is in accordance with Hamaker's law). Hence up till 40 minutes of deposition no sign of self limiting behaviour could be observed. In theory this means that deposition is possible until the suspension runs out of particles. Green density measurements were performed to give deeper insight in the deposit quality. If present, internal cavities caused by gas evolution should show in these values. And as expected a bigger difference was noted in the green density than in the visual appearance of the deposits. However, surprisingly the results show that the deposits made by UAC-EPD are denser than those typically obtained by DC-EPD from ethanol based suspensions (2). This not only means that there are no appreciable pores caused by gas evolution in the deposits made by AC-EPD of aqueous suspensions, but that the general packing is higher. Moreover the green density was higher than that of the reference samples produced by cold pressing and cold isostatic pressing (CIP'ing) (57.90 + 0.03%).
In a particular embodiment of present invention the frequency of said unbalanced signal or UAC lies between 0.1 Hz and 1 MHz, preferably between 1 Hz and 1 kHz and most preferably between 10 Hz and 200 Hz.
In a particular embodiment of present invention the frequency of said unbalanced signal or UAC has an applied signal strength lies between 1 V peak to peak and 10000V, preferably between IV and 5000 V peak to peak, more preferably between 10V and 5000V peak to peak, most preferably between 10 V peak to peak and 2000V peak to peak and especially preferably between 50 V peak to peak and 1000 V peak to peak. The resulting electric field strength, calculated as the voltage over the interelectrode distance, lies between 100 V/m and 106 V/m, preferable between 1000 V/m and 105 V/m and most preferably between 2500 V/m and 25000 V/m.
The present invention solves the problems of high voltage EDP from water in the related art by method for electrophoretic deposition in unbalanced AC electric fields (UAC-EPD). Unbalanced (asymmetric) AC electric fields (UAC) can be achieved by creating a signal in which the amplitude differs significantly for the positive and negative part, while maintaining a net integral over one period lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero,. Such UAC fields as depicted in figure 1. However the Unbalanced AC electric fields do not necessary need to have triangle form wave form. Alternatively one sinus waves on top of another sinus wave with an integral lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one time period can be used and easily enforced without sudden changes
Such AC fields have an unbalanced form, yet yield no net DC signal. Alternatively such unbalanced AC electric fields can be described as an AC electric field that is composed of signals with different amplitudes for the negative and the positive part but with an integral lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one time period. It can be AC fields in which the amplitude and the duration of the negative and the positive part differ, but the overall integral over one period is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero,.
The unbalanced AC-signal of present invention for depositing colloidal particles suspended in an aqueous medium or molecules in solution of an aqueous medium has a voltage evolution of which the positive and negative amplitude differ in absolute value.
Yet over one period of the signal the net DC-voltage, calculated by integrating the voltage in function of time, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero. An unbalanced AC-signal is a signal of which the shape of the negative and positive signal part differ, preferably in amplitude and most preferably in both amplitude and duration. However the net resulting DC-signal of said unbalanced signal, obtained by calculating the voltage average over one period, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
Wave shapes of the UAC signals EPD of present invention
Signal shapes:
The unbalances can take different shapes such as triangle, sine; square or others. A first and foremost option to generate unbalanced AC-signals is the use of a function generator. Any general shape of wave can be obtained in this manner. Care has to be taken to ensure that the voltage or current integral over one period is below the threshold for gas bubble evolution. In other words the absolute area below the positive end negative part of one signal period have to be of such size that the difference between them yields a absolute net voltage over one period smaller than 4V and preferably equal to zero. Fig 18 shows a typical example of a wave composed of two triangles. Similar results can be obtained with block waves, trapezoidal waves or waves with rounded features. When utilizing amplifiers one must however take care that the wave offered to the amplifiers input is not distorted during amplification in such a manner that a net DC- signal is generated.
A second option is to compose an unbalanced AC-signal by superimposing two symmetrical signals, which are shifted in phase and have different frequencies, on one another. Since both original signals are symmetrical and have a net DC-value of zero the resulting composed signal also has a net DC-signal equal to zero (Fig. 19)
For sinus waves this can be generalized by the following equations.
Signal 1: E1(If) = Ei x sin (ω t)
Signal 2: E2(t) = m E2 x sin (n ω t + φ)
Composed signal: E1+2(t) = Ei x sin (ω t) + m E2 x sin (n ω t + φ)
With Ei and E2 the amplitudes of the original signals, ω the angular velocity, φ the phase shift and m and n two arbitrary multiplication factors of which n differs from 1. Fig. 19 shows an example in which Ei = E2 = 1, ω= 2 π 50, n = 2 and φ = 90° or π/2 radials.
Signal A: EA(t) = sin (100 x π x t)
Signal B: EB(t) = sin (200 x π x t + π/2)
Composed signal: EA+B(O = sm (100 x π x t) + sin (200 x π x t + π/2)
The amplitude of the negative peak is almost twice the size of the amplitude of the positive signal.
Table 3 yields of alumina (SM8 grade, Baikowski) deposit made using the signal as shown in Fig. 12
UAC-EPD is an electrophoretic deposition or the process that colloidal particles suspended in a liquid medium or solved molecules in a liquid medium migrate and are deposited under the influence of the UAC fields onto an electrode or porous substrate placed in front of an electrode. Such UAC-EPD can include or can be used for electrocoating, cathodic electrodeposition, electrophoretic coating, or electrophoretic painting.
Examples of AC-fields that have an unbalanced form, yet yielding no net DC signal, are shown in Fig. 1. The amplitude and duration of the negative and positive part differ, but the overall integral over one period is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero. Electrophoretic deposition of OC- Al2O3 powder in water using the unbalanced AC signal represented in Fig. 1, resulted in smooth deposits with no visible defects. The surface quality of the deposits is comparable to that of deposits made from non-aqueous (ethanol, acetone) systems using a DC field. The deposits obtained from an aqueous suspension using a DC and unbalanced AC fields are compared in Fig. 2, clearly revealing the effect of water electrolysis in case of the DC- electrical field, the AC-electrical field the superimposition of AC on DC field.
Charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles
The unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous onto an electrode or porous substrate placed in front of an electrode is particularly suitable for the deposition of inorganic substances such as hydroxides, oxides (including glasses), carbides, nitrites, borides, carbonates, carbonitrides, metals, phosphors, phosphates, hydrates, hydrides, fluorides, sulphides, sulphates, salts and apatites some of which can be bioactive or can be biocompatible.
The unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous medium onto an electrode or porous substrate placed in front of an electrode is particularly suitable for the deposition of organics such as monomers, precursors, hydrocarbons, functional hydrocarbons, macromolecules, oligosaccharides, polysaccharides, polymers (e.g. thermoplastic polymers, thermo curing polymers, biopolymers, alginates, carrageen or other algae derived polymers, kollicoat IR, or resins, oligomers some of which can be bioactive and others biocompatible.
The unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous medium onto an electrode or porous substrate placed in front of an electrode is particularly suitable for the deposition of proteins (e.g. collagen), polynucleotides (e.g. DNA or RNA), sugars, fatty acids, amino acids, nucleotides. The unbalanced alternating current electrophoretic deposition (UAC- EPD) of present invention for depositing charged or self-charging compounds or molecules in aqueous medium from the aqueous medium onto an electrode or porous substrate placed in front of an electrode is particularly suitable for the deposition of eukaryote or prokaryote cells. It can for instance be used for the deposition of amoeba, bacteria, yeast, plant cells, mammalian cells (e.g. human cells for instance osteoblasts) fungae, and of the organelles, cell components and macromolecules thereof. It is particularly interesting that these cells organelles, cell components and macromolecules thereof are bioactive.
Negatively charged molecules are present in biological systems. The "negatively charged molecules" are meant to include molecules such as nucleic acid molecules (e.g., RNA, DNA, oligonucleotides, mixed polymers, peptide nucleic acid, and the like), peptides (e.g., polyaminoacids, polypeptides, proteins and the like). Nucleotides, pharmaceutical and biological compositions have negatively charged groups that can ion- pair with the positively charged head group of the cationic lipids of the invention. The charge or isoelectric point (pi) can be changed. For example, the chemical conversion of surface carboxyl groups of antibodies to extended primary amino groups results in the cationization of the antibody. Nonglycolated Fab (pL>9.3), mildly cationic glyco-Fab
(pI=7-9.3), mildly anionic glyco-Fab (pI=4.5-7) and strongly anionic glyco-Fab (pl<4.5) could be generated (Cancer Res. 59, pp. 422-430 View Record in Scopus Kobayashi et al. (1999)).
Food is made up of many different chemical components or parts, including vitamins, minerals, sugars, fibres, water, lipids, proteins and starches. In addition to these main nutrient components, many foods contain smaller amounts of biologically active chemicals. In plants, these are referred to as phytochemicals. Scientists can separate out all of these different components of foods. A food portion contains negatively charged molecules and positively charged molecules which by the present method of the invention can be deposited on a conductive substrate in a smooth coating and a desired thickness. Many food items contain anionic polymers.
Suitable cationic polymers are for instance selected from the group of cationic polyamines in particular, poly lysine (a polyamine that is almost completely protonated at physiological pH of 7.5), polyacrylamide, homopolymer of dimethyldiallyl ammonium chloride, 2-methacryloyloxyethyl trimethyl ammonium methosulfate, methacrylamido propyl trimethyl ammonium chloride, ethyleneimine, copolymers of acrylamide, cationic polyacrylic, dimethyldiallyl ammonium chloride, methacrylamido propyl trimethyl ammonium chloride, 2-methacryloyloxyethyl trimethyl ammonium methosulfate, Cl 8 trimethyl ammonium chloride, C18(polyoxyethylene) methyl ammonium chloride, pDMAEMA [(poly(dimethylamino)ethyl methylacrylate], chitosan, Linear pEI, PVP, DEAE-dextran, PIl, comb-type copolymers (like pLL-gr-dextran and block copolymers (like the pEG-pLL block copolymer). Chitosan is one of a few natural cationic polysaccharides that are harmless, and it has several potential functions such as antimicrobial activity. The present invention can be used to make a coat or smooth objects of chitosan. Since the majority of the waterborne bacteria and virusses have a negative charge, positive charged cationic films produced by the unbalanced alternating current (UAC) electric signals method of present invention can be used to attract such and remove them.
Typical anionic polymers are the polymers of the group consisting of poly- L- glutamate, anionic acrylic polymers, hydrogels based on anionic urethane polyether-amine polyelectrolytes, polymers of anionic urethane, carbomer and polyvinyl acetate phthalate [PVAP], Eudragit S, Eudragit L 100-55, sodium carboxymethylcellulose, dextran sulfate and Nafion®-117. Hyaluronic acid (HA is the simplest glycosaminoglycan (a class of negatively charged polysaccharides). There are many natural anionic polymers that are obtainable by the purification method of Sainz-Serp, D ; Wandrey, C: Minerva Biotechnol., 2005, p. 215-229. Anionic polymers inhibit fibrosis, scar formation and
surgical adhesions and the present method is suitable for the formation of smooth coating of such anionic polymers on medical implants, hydrogels containing carboxylate anions such as copolymer of 2-hydroxyethyl methacrylate and sodium methacrylate, anionic polymers derived from L-tyrosine. Several negatively charged microorganisms responsible for plaque generation and the negatively charged films (for instance films of bis(naphthoxy)alkane sulfonates) have a mutual repulsion effect.
The majority of waterborne bacteria and viruses are negatively charged at a pH of about 6 to about 8. Polio virus has an isoelectric point at a pH of about 7 such that only at alkaline pH will the polio virus have a negative charge. The electrokinetic property of an intact cell generally dependents upon the surface property of cells.
The objects or coating produced by the process of present invention can comprise any bio-active compound that is suitable that is ionised, partially ionised or self charging of the various therapeutic classes of bio-active agents that can be administered while using the present dosage forms include, but are not limited to: analgesic agents; anesthetic agents; antiarthritic agents; respiratory drugs; anticancer agents; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics and antiviral agents; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastic agents; anti-Parkinson drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents and other gastrointestinally active agents; antiviral agents; anxiolytics; appetite suppressants; attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) drugs; cardiovascular preparations including calcium channel blockers, CNS agents, and vasodilators; beta-blockers and antiarrhythmic agents; central nervous system stimulants; cough and cold preparations, including decongestants; diuretics; genetic materials; herbal remedies; hormonolytics; hypnotics; hypoglycemic agents; immuno-suppressive agents; leukotriene inhibitors; mitotic inhibitors; muscle relaxants; narcotic antagonists; nutritional agents, such as vitamins, essential amino acids and fatty acids; parasympatholytics; peptide drugs; psychostimulants; sedatives; steroids; sympathomimetics; and tranquilizers. Gastrointestinally active agents that can be used to be comprised in the objects or coatings according to the method of present invention include agents for inhibiting gastric acid secretion such as, but not limited to, the H2 receptor antagonists cimetidine, ranitidine, famotidine, and nizatidine, the H+ or K+-ATPase inhibitors (also referred to as
"proton pump inhibitors") omeprazole and lansoprazole, and antacids such as, but not limited to, calcium carbonate, aluminum hydroxide and magnesium hydroxide. Also included within this general group are agents for treating infection with Helicobacter pylori (H. pylori) such as, but are not limited to, metronidazole, tinidazole, amoxicillin, clarithromycin, tetracycline, thiamphenicol and bismuth compounds (e.g. bismuth subcitrate and bismuth subsalicylate). Other gastrointestinally active agents that can be administered while using the present dosage forms include, but are not limited to, pentagastrin, carbenoxolone, sulfated polysaccharides such as sucralfate, prostaglandins such as misoprostol, and muscarinic antagonists such as pirenzepine and telenzepine. Additionally included are antidiarrheal agents, antiemetic agents and prokinetic agents such as, but are not limited to, ondansetron, granisetron, metoclopramide, chlorpromazine, perphenazine, prochlorperazine, promethazine, thiethyl-perazine, triflupromazine, domperidone, trimethobenzamide, cisapride, motilin, loperamide, diphenoxylate and octreotide. Anti-microbial agents that can be used to be comprised in the objects or coatings according to the method of present invention include tetracycline antibiotics and related compounds (e.g. chlortetracycline, oxy-tetracycline, demeclocycline, methacycline, doxycycline, minocycline and roli-tetracycline); macrolide antibiotics such as, but not limited to, erythromycin, clarithromycin, and azithromycin; streptogramin antibiotics such as, but not limited to, quinupristin and dalfopristin; beta-lactam antibiotics, including penicillins (e.g., penicillin G, penicillin VK), antistaphylococcal penicillins (e.g. cloxacillin, dicloxacillin, nafcillin and oxacillin), extended spectrum penicillins (e.g. aminopenicillins such as ampicillin and amoxicillin, and antipseudomonal penicillins such as carbenicillin), cephalosporins (e.g. cefadroxil, cefepime, cephalexin, cefazolin, cefoxitin, cefotetan, cefuroxime, cefotaxime, ceftazidime and ceftriaxone) and carbapenems such as, but not limited to, imipenem, meropenem and aztreonam; aminoglycoside antibiotics such as, but not limited to, streptomycin, gentamicin, tobramycin, amikacin and neomycin; glycopeptide antibiotics such as teicoplanin; sulfonamide antibiotics such as, but not limited to, sulfacetamide, sulfabenzamide, sulfadiazine, sulfadoxine, sulfamerazine, sulfamethazine, sulfamethizole and sulfamethoxazole; quinolone antibiotics such as, but not limited to, ciprofloxacin, nalidixic acid and ofloxacin; anti-mycobacterials such as, but not limited to, isoniazid, rifampin, rifabutin, ethambutol, pyrazinamide, ethionamide, aminosalicylic and cycloserine; systemic antifungal agents such as, but not limited to, itraconazole, ketoconazole,
fluconazole and amphotericin B; and miscellaneous antimicrobial agents such as, but not limited to, chloramphenicol, spectinomycin, polymyxin B (colistin), bacitracin, nitrofurantoin, methenamine mandelate and methenamine hippurate. Anti-diabetic agents that can be used to be comprised in the objects or coatings according to the method of present invention include, by way of example, acetohexamide, chlorpropamide, ciglitazone, gliclazide, glipizide, glucagon, glyburide, miglitol, pioglitazone, tolazamide, tolbutamide, triampterine, and troglitazone. Non-opioid analgesic agents that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, apazone, etodolac, difenpiramide, indomethacin, meclofenamate, mefenamic acid, oxaprozin, phenylbutazone, piroxicam and tolmetin. Opioid analgesics that may be used in this invention include, but are not limited to, alfentanil, buprenorphine, butorphanol, codeine, drocode, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene, sufentanil and tramadol. Anti-inflammatory agents that can be used to be comprised in the objects or coatings according to the method of present invention include non-steroidal anti-inflammatory agents, e.g. propionic acid derivatives such as, but not limited to, ketoprofen, flurbiprofen, ibuprofen, naproxen, fenoprofen, benoxaprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, alminoprofen, butibufen, fenbufen, apazone, diclofenac, difenpiramide, diflunisal, etodolac, indomethacin, ketorolac, meclofenamate, nabumetone, phenylbutazone, piroxicam, sulindac and tolmetin. Suitable steroidal anti-inflammatory agents include, but are not limited to, hydrocortisone, hydrocortisone-21-monoesters (e.g. hydrocortisone-21-acetate, hydrocortisone-21-butyrate, hydrocortisone-21 -propionate, hydrocortisone-21 -valerate), hydrocortisone- 17, 21-diesters (e.g. hydrocortisone- 17,21 - diacetate, hydrocortisone-17-acetate-21-butyrate, hydrocortisone-17,21-dibutyrate), alclometasone, dexamethasone, flumethasone, prednisolone and methylprednisolone. Anticonvulsant agents that can be used to be comprised in the objects or coatings according to the method of present invention, by way of example, azetazolamide, carbamazepine, clonazepam, clorazepate, ethosuximide, ethotoin, felbamate, lamotrigine, mephenyloin, mephobarbital, phenyloin, phenobarbital, primidone, trimethadione, vigabatrin, topiramate, and benzodiazepines. CNS and respiratory stimulants that can be used to be comprised in the objects or coatings according to the method of present invention, but are not limited to, xanthines such as caffeine and theophylline; amphetamines such as amphetamine,
benzphetamine hydrochloride, dextroamphetamine, dextroamphetamine sulfate, levamphetamine, levamphetamine hydrochloride, methamphetamine, and methamphetamine hydrochloride; and miscellaneous stimulants such as methylphenidate, methylphenidate hydro-chloride, modafinil, pemoline, sibutramine and sibutramine hydrochloride. Neuroleptic agents that can be used to be comprised in the objects or coatings according to the method of present invention include antidepressant drugs, antimanic drugs and antipsychotic agents. Suitable antidepressant drugs include:
(a) tricyclic antidepressants such as, but not limited to, amoxapine, amitriptyline, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline and trimipramine,
(b) serotonin re-uptake inhibitors such as, but not limited to, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline and venlafaxine,
(c) monoamine oxidase inhibitors such as, but not limited to, phenelzine, tranylcypromine and (-)-selegiline, and (d) other atypical antidepressants such as, but not limited to, nefazodone, trazodone and venlafaxine. Suitable anti-manic and anti-psychotic agents include:
(a) phenothiazines such as, but not limited to, acetophenazine, acetophenazine maleate, chlorpromazine, chlorpromazine hydrochloride, fluphenazine, fluphenazine hydrochloride, fluphenazine enanthate, fluphenazine decanoate, mesoridazine, mesoridazine besylate, perphenazine, thioridazine, thioridazine hydrochloride, trifluoperazine, and trifluoperazine hydrochloride,
(b) thioxanthenes such as, but not limited to, chlorprothixene, thiothixene, and thiothixene hydrochloride, and
(c) other heterocyclic drugs such as, but not limited to, carbamazepine, clozapine, droperidol, haloperidol, haloperidol, decanoate, loxapine succinate, molindone, molindone hydrochloride, olanzapine, pimozide, quetiapine, risperidone and sertindole. Hypnotic agents and sedatives that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, clomethiazole, ethinamate, etomidate, glutethimide, meprobamate, methyprylon, Zolpidem and barbiturates (e.g. amobarbital, apropbarbital, butabarbital, butalbital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital and thiopental).
Anxiolytics and tranquilizers that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to,
benzodiazepines (e.g. alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam and triazolam), buspirone, chlordiazepoxide and droperidol. Anticancer and antineoplastic agents that can be used to be comprised in the objects or coatings according to the method of present invention, but are not limited to, paclitaxel, docetaxel, camptothecin and its analogues and derivatives (e.g. 9-aminocamptothecin, 9- nitrocamptothecin, 10-hydroxycamptothecin, irinotecan, topotecan and 20-O- β- glucopyranosyl camptothecin), taxanes (e.g. baccatins, cephalomannine and their derivatives), carboplatin, cisplatin, interferon-α 2A, interferon-α 2B, interferon-α N3 and other agents of the interferon family, levamisole, altretamine, cladribine, tretinoin, procarbazine, dacarbazine, gemcitabine, mitotane, asparaginase, porfimer, mesna, amifostine, mitotic inhibitors including podophyllotoxin derivatives such as, but not limited to, teniposide and etoposide, and vinca-alkaloids such as, but not limited to, vinorelbine, vincristine and vinblastine. Antihyperlipidemic or lipid-lowering or hyperlipidemic agents that can be used to be comprised in the objects or coatings according to the method of present invention, but are not limited to, HMG-CoA reductase inhibitors such as atorvastatin, simvastatin, pravastatin, lovastatin and cerivastatin, and other lipid- lowering agents such as, but not limited to, clofibrate, fenofibrate, gemfibrozil and tacrine. Anti-hypertensive agents that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, arnlodipine, benazepril, darodipine, dilitazem, diazoxide, doxazosin, enalapril, eposartan, losartan, valsartan, felodipine, fenoldopam, fosinopril, guanabenz, guanadrel, guanethidine, guanfacine, hydralazine, metyrosine, minoxidil, nicardipine, nifedipine, nisoldipine, phenoxybenzamine, prazosin, quinapril, reserpine and terazosin. Cardiovascular preparations that can be used to be comprised in the objects or coatings according to the method of present invention include, by way of example, angiotensin converting enzyme (ACE) inhibitors such as, but not limited to, enalapril, l-carboxymethyl-3-l-carboxy-3- phenyl-(lS)-propylamino-2,3,4, 5-tetrahydro-lH-(3S)-l-benzazepine-2-one, 3-(5-amino-l- carboxy-l-S-pentyl)amino-2,3,4, 5-tetrahydro-2-oxo-3-S-l-H-benza-zepine-l -acetic acid or 3-(l-ethoxycarbonyl-3-phenyl-(lS)-propylamino)-2,3,4,5-tetrahydro-2-oxo-(3S)-ben zazepine-1 -acetic acid monohydrochloride; cardiac glycosides such as, but not limited to, digoxin and digitoxin; inotropes such as amrinone and milrinone; calcium channel blockers
such as, but not limited to, verapamil, nifedipine, nicardipene, felodipine, isradipine, nimodipine, bepridil, amlodipine and diltiazem; beta-blockers such as, but not limited to, atenolol, metoprolol; pindolol, propafenone, propranolol, esmolol, sotalol, timolol and acebutolol; antiarrhythmics such as, but not limited to, moricizine, ibutilide, procainamide, quinidine, disopyramide, lidocaine, phenyloin, tocainide, mexiletine, flecainide, encainide, bretylium and amiodarone; cardioprotective agents such as dexrazoxane and leucovorin; vasodilators such as nitroglycerin; and diuretic agents such as, but not limited to, hydrochlorothiazide, furosemide, bumetamide, ethacrynic acid, torsemide, azosemide, muzolimine, piretanide and tripamide. Anti-viral agents that can be used to be comprised in the objects or coatings according to the method of present invention include, but are not limited to, anti-herpes agents such as acyclovir, famciclovir, foscamet, ganciclovir, idoxuridine, sorivudine, trifluridine, valacyclovir and vidarabine; anti-retroviral agents such as didanosine, stavudine, zalcitabine, tenovovir and zidovudine; and other antiviral agents such as, but not limited to, amantadine, interferon- alpha, ribavirin and rimantadine. Sex steroids that can be used to be comprised in the objects or coatings according to the method of present invention include progestogens such as, but not limited to, acetoxypregnenolone, allylestrenol, anagestone acetate, chlormadinone acetate, cyproterone, cyproterone acetate, desogestrel, dihydrogesterone, dimethisterone, ethisterone (17α-ethinyl-testosterone), ethynodiol diacetate, fluorogestone acetate, gestadene, hydroxyprogesterone, hydroxyprogesterone acetate, hydroxyprogesterone caproate, hydroxymethylprogesterone, hydroxymethylprogesterone acetate, 3- ketodesogestrel, levonorgestrel, lynestrenol, medrogestone, medroxyprogesterone acetate, megestrol, megestrol acetate, melengestrol acetate, norethindrone, norethindrone acetate, norethisterone, norethisterone acetate, norethynodrel, norgestimate, norgestrel, norgestrienone, normethisterone and progesterone. Also included within this class are estrogens, e.g. β-estradiol (i.e. l,3,5-estratriene-3,17β-diol, or 17β-estradiol) and its esters, including estradiol benzoate, valerate, cypionate, heptanoate, decanoate, acetate and diacetate; 17α-estradiol; ethinylestradiol (i.e. 17α-ethinylestradiol) and esters and ethers thereof, including ethinylestradiol-3-acetate and ethinylestradiol-3-benzoate; estriol and estriol succinate; polyestrol phosphate; estrone and its esters and derivatives, including estrone acetate, estrone sulfate, and piperazine estrone sulfate; quinestrol; mestranol; and conjugated equine estrogens. Androgenic agents, also included within the class of sex steroids, are drugs such as the naturally-occurring androgens androsterone, androsterone
acetate, androsterone propionate, androsterone benzoate, androstenediol, androstenediol- 3- acetate, androstenediol- 17-acetate, androstenediol-3,17-diacetate, androstenediol-17- benzoate, androstenediol-3-acetate-17-benzoate, androstenedione, dehydroepiandrosterone (DHEA or prasterone), sodium dehydro-epiandrosterone sulfate, 4-dihydrotestosterone (DHT or stanolone), 5α-dihydrotestosterone, dromostanolone, dromostanolone propionate, ethylestrenol, nandrolone phenpropionate, nandrolone decanoate, nandrolone furylpropionate, nandrolone cyclohexanepropionate, nandrolone benzoate, nandrolone cyclohexanecarboxylate, oxandrolone, stanozolol and testosterone; pharmaceutically acceptable esters of testosterone and 4-dihydrotestosterone, typically esters formed from the hydroxyl group present at the C- 17 position, including, but not limited to, the enanthate, propionate, cypionate, phenylacetate, acetate, isobutyrate, buciclate, heptanoate, decanoate, undecanoate, caprate and isocaprate esters; and pharmaceutically acceptable derivatives of testosterone such as, but not limited to, methyl testosterone, testolactone, oxymetholone and fluoxymesterone. Muscarinic receptor agonists that can be used to be comprised in the objects or coatings according to the method of present invention include, by way of example, choline esters such as, but not limited to, acetylcholine, methacholine, carbachol, bethanechol (carbamylmethylcholine), bethanechol chloride, cholinomimetic natural alkaloids and synthetic analogues thereof, including pilocarpine, muscarine, McN- A-343 and oxotremorine. Muscarinic receptor antagonists that may be used in this invention include belladonna alkaloids or semi- synthetic or synthetic analogues thereof such as, but not limited to, atropine, scopolamine, homatropine, homatropine methyl bromide, ipratropium, methantheline, methscopolamine and tiotropium.
US 5,145,684 discloses particles consisting essentially of 99.9 to 10% by weight of a crystalline drug substance having a solubility in water of less than 10 mg/ml, said drug substance having a non-crosslinked surface modifier adsorbed an the surface thereof in an amount of 0.1 to 90% by weight and sufficient to maintain an effective average particle size of less than about 400 nm. In particular it discloses a modified steroid A aqueous dispersion, comprising 5% steroid A, with a particle size distribution ranging from about 68 to 520 nm and a number average particle size of 204 nm. US 5,503,723 discloses refining a nanoparticle dispersion by placing it between two electrodes and applying an electric field between said electrodes, wherein the dispersion consists essentially of particles of poorly soluble crystalline therapeutic or diagnostic agent, wherein 99% of the particles have a particle size below 400 nm and are associated with a surface modifier
which is capable of stabilizing the nanoparticles. In particular, it describes a danazol dispersion wherein 10% of the particles are reduced in size down to 180 nm. US 5,858,410 discloses a drug carrier, prepared using the jet stream principle and using surfactants such as Tween 80 and mannitol, comprising particles of a therapeutic agent which is insoluble, only sparingly soluble or moderately soluble in water, aqueous media and/or organic solvents, wherein the therapeutic agent has an average diameter below 1,000 nm and the proportion of particles larger than 5 μm in the total population is less than 0.1%. In particular, it describes aqueous nanosuspensions comprising 2-15% of a substituted pteridine and at least 0.1% Tween 80 wherein the average particle diameter is in a range from 200 to 800 nm. It also teaches that for special tetracaine compositions with a low (1%) drug concentration, nanosuspensions with an average particle size of 91 nm may be obtained. US 5,922,355 discloses preparing microparticles of a water-insoluble or poorly soluble compound by, prior to or during reducing particle size (e.g. by sonication, homogenization, milling, microfluidization and precipitation, or recrystallization and antisolvent precipitation), mixing said particles with (a) a phospholipid and (b) at least one surfactant such that the concentration of phospholipid and surface modifier in the suspension or solid form is in the range of 0.1 to 50%, and thereafter applying energy to the mixture. It specifically describes drug formulations wherein the drug concentration is from 2 to 5%, wherein the mean particle size is between 35 and 98 nm and wherein there is no substantial variation in the mean particle size after one or more weeks storage of the formulations at 4° C. U.S. Pat. No. 6,221,400 discloses nanocrystalline formulations of HIV protease inhibitors wherein the average particle size is below 400 nm. It specifically describes nanoparticulate compositions of indinavir wherein the mean size of the nanoparticles is between 127 and 267 nm. International Patent application WO 02/055059 discloses methods involving both a water-miscible first solvent and an aqueous second solvent for preparing sub-micron sized particles of an organic compound. Using these methods, suspensions preparations wherein the average particle diameter is in the range from 180 to 700 nm. Thus a common feature of the prior art publications is that it is extremely difficult to obtain drug suspensions wherein the average particle size is within the nanometer range, preferably below 500 nm. This was apparently achieved only in very specific drugs, provided further that the drug concentration in the suspension is low, e.g. below 5% by weight. Because it is a sparingly water-soluble, normally crystalline active agent, itraconazole has attracted many attempts to improve its bioavailability. For instance,
US 6,346,533 discloses a method for obtaining itraconazole in an amorphous form exhibiting an improved bioavailability and having a particle diameter 0.5 to 10 μm. US 6,497,905 discloses converting crystalline itraconazole into its amorphous form as a solid solution of a normally hydrophobic vehicle such as glyceryl monostearate, a monoglyceride, a diglyceride, a triglyceride, or a wax. This solid solution may be used as a component of a granular particle wherein itraconazole is present at about 5 to 60% by dry weight. Particle size of this granular particle is not specified. International Patent application WO 2004/043580 discloses an emulsification method comprising flowing, conducting or circulating a pre-mix of two or more immiscible liquids, said pre-mix preferably comprising at least a hydrophilic liquid and at least a lipophilic liquid, through one or more magnetic fields under conditions to emulsify the said pre-mix. Although emulsions prepared according to this method may be included into veterinary or pharmaceutical compositions, this document does not refer to the solubilization of poorly soluble drugs as such. US 2007/0082054, Particle size reduction of bioactive compounds, describes a method for reducing the average size of biologically active compound solid particles or agglomerates suspended in a liquid by flowing one or more times said liquid having biologically active compound solid particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound solid particles or agglomerates by at least 25%, wherein the linear flow rate of said liquid through each said magnetic field is between 0.25 and 25 m/s. These methods of particle size reduction can be used to reduce the average size of the particles in suspension and to improve the deposition of the reduced size colloidal particles suspended in an aqueous medium or in an aqueous medium slurry or the reduced size particles that stabilize an emulsion under the influence of an electric field onto an electrode or porous substrate placed in front of an electrode whereby the electric fields involve unbalanced AC electric fields (UAC-EPD).
The material selected for coating are those upon which the molecules may be deposited via electrochemical deposition under an unbalanced alternating voltage. Suitable materials are electrically conductive, and may include metals (e.g., aluminum, antimony, cadmium, chromium, cobalt, copper, gold, iron, lead, magnesium, mercury, nickel, palladium, platinum, silver, tin, tungsten, zinc), metal alloys (steel, brass, bronze, etc.), semiconductors (e.g., silicon, gallium or germanium semiconductor materials), and/or conductive polymers (e.g., polypyrrole). The electrodes used in present invention can for
instance comprise conductive polymers. Common classes of organic conductive polymers include poly(acetylene)s, poly(pyrrole)s, poly(thiophene)s, poly(aniline)s, poly(fluorene)s, poly(3-alkylthiophene)s, polytetrathiafulvalenes, polynaphthalenes, poly(p-phenylene sulfide), poly(para-phenylene vinylene)s, polyethelene terephthalate Dacron®, nylon, silk or other natural or synthetic polymeric material.. Classically, these linear backbone polymers are known as polyacetylene, polyaniline, etc. "blacks" or "melanins".
EXAMPLES
The suspensions were prepared using fresh deionised water obtained from a commercial ion exchange setup (Sation Aqualab 50) and with an initial conductivity of 0.04μS/cm. As powder SM8-grade α-alumina (Baikowski) was chosen and a constant concentration of 200g/L was used for all experiments. The powder was charged by adjusting the pH below the IEP by means of nitric acid (Analytical reagent grade, 65%, Fluka) (Table T). The IEP itself was determined by a potentiometric titration (Matec ESA 9800) (Fig. 6) while the particle size was measured using light scattering (Malvern Mastersizer+) (Fig. T). In order to disperse the powder each suspension was agitated 15 minutes on a magnetic stirring plate, followed by an additional 15 minutes in an ultrasonic bath (Branson 2510). Electrophoretic deposition was carried out in a teflon cell with two electrodes placed vertically at 3.5 cm distant from each other. The area available for deposition was 9 cm2. The conductive polymer (carbon doped poly oxymethylene) deposition electrode was coated with graphite (NGS Dragon Seal Graphite) before deposition. Prior and after each experiment the temperature and conductivity (WTW inolab cond level T) of the suspension is recorded (2). The signal (1) was generated using a function generator (HP 3314A) and amplified with an operational amplifier (Trek PZD 700 m/s). An amplitude of 500 volts peak to peak (Vp_p) and an asymmetry factor of 4 was used for all experiments. The deposits were consequently dried at room temperature for 24 hours. The yield was recorded by weighing the electrode prior to deposition and after drying. The green density of the samples produced using 40 minutes deposition time and a frequency of 5Hz or higher was measured using the Archimedes principle. A lacquer with known density (Enthone B. V.) was applied to seal of the pores prior to submerging the samples. Before encapsulation any carbon transferred from the electrode to the deposit was
removed. In addition three green density reference samples were produced by uniaxial cold-pressing SM8 powder into pellets, followed by CIP'ing (isostatic pressing) at 300MPa. White light interferometry (Wyko NT3300, Veeco) was used to compare the deposit surface roughness of the produced samples with those produced by traditional EPD.
Deposit characterization.
Visual inspection shows no sign of large defects such as gas bubbles breaking the surface of the deposits produced using the unbalanced AC-fields. The surface quality of the deposits is similar to those produced by EPD from ethanol-based suspensions using DC fields. White light interferometry confirms that the overall roughness is similar for samples produced using both techniques (Ra = ± 120 nm).
EXAMPLE 1: Controllability of the process OC-AI2O3 was deposited using the technology of present invention. The deposition rate of OC-AI2O3 versus the symmetry of the applied signal V1, V2, tl5 12 (as defined in Figure 1). The suspension consisted of a 200 g/L SM8 in water containing 4.10"4 M HNO3.
The more symmetric signals the smaller deposition rates observed. For instance symmetry of the signal was varied, by varying the height (amplitude) and width (pulse duration) of the triangular waves while maintaining a total period of 20 ms, a peak to peak height of 500 V and a net integral lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, over one period. The asymmetry factor is determined as the ratio between the pulse heights, which is equal to the ratio of the pulse widths. Fig. 3 shows that the deposition rate is zero when the applied field is symmetric
(asymmetry factor equal to one) because no net electrophoresis occurs under the influence of symmetric AC fields. As the asymmetry factor increases the deposition rate increases as expected from equation (1). A threshold exists below which there is no deposition.
At higher asymmetry factors in Figure 3 the average deposition rate during AC-EPD was lower than in DC-EPD. This is due to the fact that only a fraction of the time is used to drive the particles towards the deposition electrode. When taking this actual deposition time into account, the instantaneous deposition rate is higher than typically observed in ethanol (Anne, G., et al. Journal of the American Ceramic Society 89, 823-828 (2006))
When depositing A12O3 from ethanol using a DC-field of 200 V, which is the average height of the high amplitude pulse used in the AC-EPD experiments with an asymmetry of 4, the deposition rate is 2.7 g/m2s. The deposition rate for the corresponding AC-field is 0.82 g/m2s but since deposition occurs during 1/5 of the time, the instantaneous deposition rate is 4.1 g/m2s.
In order to confirm the general nature of the method, conductive titanium diboride and negatively charged titanium dioxide powder were also deposited. The obtained deposits are of similar quality as those obtained with the non conductive positively charged alumina powder. No drying cracks were formed, which is typical for deposits with a high green density. The green density of the Al2O3 deposits obtained by AC-EPD is 60.6 +
0.9% (5 measurements, deposits made with 200 g/L Al2O3 (SM8, Baikowski) suspensions with 4 10"4 M HNO3 and deposited with 500 Vp_p at 50 Hz). The green density of deposits made by DC-EPD from alcohol based suspensions using the same particles varies between 51 and 58% (Anne, G., et al. Journal of the American Ceramic Society 89, 823-828 (2006) and Anne, G., et al. Journal of the European Ceramic Society 26, 3531-3537 (2006)). In comparison, SM8 grade Al2O3 samples isostatically pressed at 300 MPa have a green density of 57.9 + 0.03%, while the theoretical maximum density for a random stacking of monomodal spheres is 64% (German, R. M. Metal Powders Industries Federation, Princeton, New Jersey, 1989 and To, L. T. & Stachurski, Z. H. Journal of N on- Crystalline Solids 333, 161-171 (2004)).
Present invention revealed that unbalanced AC-EPD allows the electrophoretic deposition from aqueous suspensions at high voltages. AC-EPD avoids the formation of gas bubbles on the electrode during electrophoresis from the electrolysis of water. Moreover, AC-EPD allows electrophoretic deposition from aqueous instead of organic solvent suspensions, which is strongly preferred from an environmental, safety and economic perspective, while maintaining the surface quality and processing rate of DC- EPD using organic solvents.
EXAMPLE 2: Material and Methods Fresh deionised water with an initial conductivity of 0.04 μS/cm and prepared with a commercial ion exchange setup (Sation Aqualab 50) was used for all suspensions. Commercially available OC-Al2O3 (Baikowski grade SM8), TiB2 (H.C.Starck grade F) and rutile TiO2 (Kemira grade Rutilex) powders were used for experimentation. The TiO2 was
boiled and washed in a dialysis cell prior to use. No charging agent was added to the TiB2 suspension while the TiO2 was charged using KOH (Chem Lab 0.1 mol/1 standard). HNO3 (Fluka 65%) was used as a charging agent for the experiments with alumina. For each experiment a new suspension was prepared using 50 ml freshly prepared water and the indicated amount of powder and charging agent (Table 1). The suspensions were magnetically stirred for 15 minutes; followed by 15 minutes of treatment in an ultrasonic bath (Branson 2510), subsequently followed by 15 minutes of stirring on a magnetic plate. A programmable function generator (HP 3314A) was used to generate the unbalanced AC signal. A bipolar operational power supply and amplifier (Kepco BOP IOOOM or Trek PZD 700m/s) were used to amplify this by a factor of 100 or 200. The resulting signal, with a peak to peak amplitude of 500 V and a frequency of 1 to 50 Hz, was monitored with a digital oscilloscope (Fluke 97 50MHz Scopemeter). One period of the signal is depicted in Fig. 1. Deposition was carried out for 1200 s in a vertical cell equipped with conductive polymer (carbon doped poly oxy methylene (POM)) or stainless steel deposition electrodes and stainless steel counter electrodes with an electrode surface of 9 cm2 and a separation distance of 3.5 cm. The deposition electrode is coated with graphite prior to deposition in order to ensure easy removal of the deposit after drying. The deposit is formed on the electrode that is negatively, respectively positively charged during the high amplitude section of the signal for the Al2O3, respectively TiB2 and TiO2 powder. The suspension conductivity and temperature was measured before each experiment (WTW inoLab Cond Level 2 equipped with a WTW LR 325/01 probe). All deposits were visually inspected for defects, and weighed in order to determine the yield. White light interferometry (Wyko NT3300, Veeco) was used to measure the deposit surface roughness. The green density as a percentage of the theoretical density was determined using the Archimedes method with ethanol as solvent and encapsulation with a lacquer with known dry density (Enthone B. V., The Netherlands). The green density of SM8 samples isostatically pressed into a cylindrical shape at 300 MPa was measured to be 57.90 + 0.03%.
Aluminium oxide (alumina or aloxite) is an amphoteric oxide of aluminium with the chemical formula Al2O3 that can react as either an acid or base. Other suitable amphoteric oxides that are suitable for the UAC-EPD present invention are the amphoterics comprising zinc, tin, lead, aluminium, and beryllium and amphoteric oxides of most metalloids (for instance Boron (B), zirconium (Zr), Silicon (Si), Germanium (Ge), Arsenic (As), Antimony (Sb), Tellurium (Te) and Polonium (Po)) and the amino acids, proteins,
sugars, fatty acids or nulceotides which have amine and carboxylic acid groups or such amino acids and protein comprised in a suspended particles or a cell or a fragment or organelle thereof for instance a prokaryote cells such as cell of the bacteria or Archaea or an eukaryote cell such as the animals, plants, fungi, and protests cells. The organelles, cell components or macromolecules of eukaryotic cells such as chloroplast (plastid), endoplasmic reticulum, Golgi apparatus, Mitochondrion, Vacuole, Nucleus, Organelle/Macromolecule, acrosome, autophagosome, centriole, cilium, glycosome, glyoxysome, hydrogenosome, lysosome, melanosome, mitosome, myofibril, nucleolus, parenthesome, peroxisome, ribosome or vesicle which have amine and carboxylic acid groups can be deposited by UAC-EPD.
Prokaryotic organelles, cell components and macromolecules such as carboxysome, chlorosome, flagellum, magnetosome, nucleoid, plasmid, ribosome or thylakoid which have amine and carboxylic acid groups can be deposited by UAC-EPD.
Titanium dioxide, also known as titanium(IV) oxide or titania, is the naturally occurring oxide of titanium, chemical formula TiO2. It can be used as a pigment, it is then called titanium white, Pigment White 6, or CI 77891. Other oxides suitable for the UAC- EPD of present invention are titanium oxides in titanium alloyed with iron, aluminium, vanadium, molybdenum.
EXAMPLE 3: characterization
The Archimedes method for green density determination:
The green density is a value that relates to the particle packing in the formed object, and therefore is often used as a measure of the quality of the formed object. This value is traditionally stated as a percentage of the theoretical density of the material. For the measurement, the mass of the object is recorded. In order to include the interparticle porosity the object is coated with a lacquer that seals off this porosity, and after drying the mass of the coated object is registered as well. The volume of the coated object is measured by submerging it in a solvent of known density and measuring the buoyancy. The Archimedes principle is used to calculate the total volume of the coated object. From the weight difference before and after coating, the volume of the lacquer can be calculated and subtracted from the total volume. The density of the sealing lacquer is determined previously by coating a substrate of known weight and density followed by measuring the volume of coating using the Archimedes method.
Powder particle information:
In order to assess particle packing in green structures data on the particle size distribution and particle morphology is needed. Hence for each powder used in experimentation the particles size is measured (Fig. 4) and the morphology is visualized using electron microscopy (Fig. 5). The used SM8 grade alumina depicts a mono modal particle size distribution. The SM8 powder has an irregular morphology which is closer to spherical particles than to platelets or needles.
Electrophoretic mobility dependence on solvent system:
In order to illustrate the dependence of the electrophoretic mobility on the solvent system, potentiometric titrations were carried out and the electrophoretic mobility was measured as a function of the pH using the electro-acoustic technique (ESA 9800, Matec). For this, a 2.5 vol% SM8 alumina powder suspension was prepared by stirring and ultrasonification. An electrolyte background of 10-3 M KCl (IM KCl Titrimetric standard, Prolabo) was used. Prior to titration, the pH was adjusted to a base value by addition of KOH (for the aqueous suspension with 0.1M KOH titrimetric standard, Prolabo; for the ethanol based suspension with 0.1M KOH, Acros, in absolute ethanol, Prolabo). The suspensions were titrated with nitric acid (diluted in the solvent to 0.1M from 65% HN03, Fluka).
The effectiveness of a solvent / powder combination for use in electrophoretic deposition is determined by this mobility - pH curve. Just as for the surface charge, powder particles often show a zero zeta potential value at a specific pH called the iso- electro point (IEP). As is well known the pH is the negative logarithm of the activity of protons in a solvent. A direct consequence of this is that only protonic solvents can have a pH. Because the dissociation of the solvent itself plays an important role in the activity of the protons, pH scales depend on the solvent used, hence the term operational pH. For water, this scale conventionally ranges from 0 to 14, with a neutral pH value of 7. In comparison, the neutral pH in pure ethanol is 9.8, while the scale ranges from 0 to 19.6. Mixtures of both solvents will yield pH-scales located between both scales of the pure solvents. As a result of the above, the iso-electric point (IEP) will shift with the solvent used (Fig. 6).
Since the surface charge of most particles depends on the interaction with the solvent, specifically by interaction with the dissociated forms of the solvent, solvents that have a higher dissociation constant will facilitate the charging of the particles, in turn causing higher mobility and zeta potentials (Fig. 6). Hence solvents with higher dissociation constants are preferentially used for the preparation of stable suspensions and EPD.
Because most oxide powders contain hydrate water, unless they were specifically dried at high temperatures, water will always play a role in the charging of these particles even if no additional water has been introduced in the system.
Particle clustering and deposit formation in AC fields
The formation of almost perfectly stacked monolayers of particles has been observed in electrophoretic deposition. This effect has been attributed to electrohydrodynamic and electro-osmotic flow (EHF and EOF), which drive the particles together near and on the electrode. Since both flows are present in low frequency AC systems as well, these will play a role in the deposition of particles in AC-EPD. In order to confirm this, a flow cell was mounted on an optical microscope and the deposition of styrene particles in a 50 Hz unbalanced field was monitored (Fig. 7).
Influence of frequency and amplitude: 50 Hz is the maximum attainable frequency with a HP 3314A function generator for a programmed signal while maintaining sufficient resolution. Deposits were also made with 20, 5 and 1 Hz signals (Fig 8). The yield increases as the frequency increases but starts to level off above about 20 Hz. The reproducibility of the yield data is highest at 50 Hz. Hence this frequency was chosen for most experiments. At 1 Hz, the deposits were so thin that they warped during drying and cracked under their own weight. Despite of this, the deposits remain free of gas bubbles even at frequencies as low as 1 Hz and the high green density is maintained.
In DC-EPD, the field strength is increased to improve the deposition rate. However, too strong fields are known to yield unstable systems resulting in lower surface quality deposits. In order to investigate the influence of the field strength, the amplitude was increased to 750Vp-p during AC-EPD. Contrary to the expectation, the deposit yield decreased to 0.569g over 40 minutes while employing this stronger field. At this point, the only explanation that can be offered is that the inverse field strength increases with the
amplitude, causing resuspension of a larger fraction of the deposited particles reducing the overall deposition rate. A second but more obvious disadvantage of the higher applied voltage is that the current increases proportionally. The higher current leads to an increased temperature, which is detrimental for the deposition rate and deposit quality.
Deposition yield in function of time:
DC-EPD from ethanol suspensions typically shows a self-limiting behavior when working under constant voltage conditions (Anne, G., et al. Journal of the American Ceramic Society 89, 823-828 (2006)). The possible reason for this behavior is the presence of thick double layers in the still porous deposit which hamper the free flow of ions. Since double layers are typically thinner in aqueous environment, the self-limiting behavior is unlikely to occur in water. Instead, the deposition rate remains constant and the yield increases linearly with time (Fig. 8), suggesting the possibility of an unlimited deposit thickness.
Temperature changes due to the applied field:
Joule heat losses occurring in the suspension system are one of the main practical concerns when performing electrophoretic deposition, causing unstable suspensions and/or deposits of inferior quality. Typically, one tries to restrict the current flowing through a cell by using low conductivity systems or current controlled electrophoretic deposition. The same applies when using water in alternating fields for electrophoretic deposition. Hence care has been taken to monitor the suspension heating by measuring the suspension temperature before and after deposition.
For direct comparison between DC and AC-EPD, an additional set of experiments was performed. First 125 ml of a 200 g/L aqueous SM8 suspension containing 4 10"4 M HN03 was prepared using the experimental scheme described in the main article. The initial conductivity was measured to be 25.9 μS/cm. This suspension was placed in a horizontal EPD setup as described by Anne (Anne, G., et al. Journal of the American Ceramic Society 89, 823-828 (2006)). The suspension was recirculated through a stirred external vessel in which a combined conductivity and temperature probe was placed. This probe was used to log both temperature and conductivity simultaneously as a function of time. Finally a 50 Hz 500 Vp-p signal was applied for 20 minutes and a deposit was formed. Similarly 200 g/L SM8-ethanol suspensions were prepared. The conductivity of
the ethanol suspensions was brought to 25μS/cm using 0.1N HN03 in ethanol. One suspension was subjected to 200 V DC while the other was deposited using the same unbalanced field as the aqueous suspension.
As shown in Fig. 9, the temperature of all systems decreases as a function of time. The initial temperature of the suspensions is above room temperature due to the ultrasonification needed to disperse the particles. Because less heat is generated in the system than transported to the environment, the temperature gradually decreases. The slower reduction in temperature of the aqueous system is either due to a higher Joule heat generation in the suspension or a slower transport of heat to the environment. These experiments confirm previous measurements in a smaller vertical EPD cell, where temperature increases during EPD were limited. The temperature increase during 40 minutes deposition from a 200 g/L suspension containing 4 10"4M HNO3 utilizing a 1 to 50Hz 500Vp-p signal never exceeded 50C. Instead, an equilibrium was reached between the heat generated in the cell (in essence a square Teflon cup with 10 mm thick walls) and the heat transported towards the environment.
Deposit surface quality:
Smooth high quality layers are a hallmark feature attributed to coatings and objects produced by electrophoretic deposition. Hence any evolution in this field of research is only useful if it is able to deliver the same or even better surface quality. In order to check whether aqueous deposition using unbalanced AC-fields delivers deposits of at least the same surface quality as those produced by conventional EPD, surface roughness measurements using white light interferometry (Wyko NT3300, Veeco) were performed.
As shown in Fig. 10 and Fig. 11, there is no significant difference between the produced deposits. Both deposits have a Ra roughness of about 118 nm, which is roughly one fourth of the particle size. The deposited layers show no evidence of deposited agglomerates.
Example 4 on AAD-EPD of emulsions stabilized by charged solid particles
UAC-EPD can be used to form deposits from emulsions stabilized by charged solid particles.
All emulsions were prepared with SM8-grade alumina (Baikowski), fresh deionized water and with an initial conductivity of 0.04 μS/cm obtained from a commercial ion exchange setup (Sation Aqualab 50) and cyclohexane (Analytical reagent grade, Prolabo).
The exact compositions of the mixtures are given in Table 4. In a first step 2 suspensions are prepared by subsequently stirring for 15 minutes, followed by 15 minutes ultrasonification (Branson 2510) and an additional 15 minutes of stirring. During EPD, a 0.5 M propionic acid solution (Analytical reagent grade, Prolabo), and a 0.1 M nitric acid solution (Analytical reagent grade, 65%, Fluka) were used as charging agent as indicated in Table 4. In a second step the cyclohexane is added to the suspension containing the propionic acid and vigorously mixed for 30 minutes using a small size lab mixer (Lab egg, Ika). The size of the droplets is measured en shown in Fig. 14. After this the second suspension is added to the emulsion and gently stirred to homogenise the suspension / emulsion mixture. The powder in this second suspension is intended to co-deposit with the droplets in order to form a solid structure in between the deposited cyclohexane. These mixtures are then placed in the cell used for electrophoretic deposition.
The EPD experiments were carried out in a cell with vertically placed electrodes with a separation distance of 3.5 cm and an effective area of 9 cm2. The deposition electrode consists of a conductive polymer plate (carbon doped polyoxymethylene (POM)), while stainless steel is used as counter electrode. Prior to EPD, the polymer electrode was dip- coated with graphite (Dragon Seal Graphite, NGS) in order to ensure easy removal of the deposit. The emulsion / suspension system was recirculated using a peristaltic pump (Watson-Marlow 505 Du) Electrophoretic deposition was performed using an unbalanced alternating signal with a frequency of 50 Hz and an amplitude of 500 Vp_p (Fig. 15b). This signal was applied using a function generator (HP 3314A) combined with an operational amplifier (Trek PZD 700 m/s). EPD was carried out during 20 minutes. The deposits were dried at room temperature for 24 hours. The yield was recorded by weighing the electrode prior to deposition and after drying. Finally, the deposits were consolidated by pressureless sintering in air at 14000C for 30 minutes, with a heating and cooling rate of 10°C/min (Nabertherm HT16/17).
Polished cross-sections of each sample, shown in Fig. 16, were inspected using scanning electron microscopy (FEI XL30 FEG).
Table 4. Composition of the investigated mixtures
The present invention thus concerns the use of UAC-EPD to form deposits from emulsions stabilized by charged solid particles. The solid particle emulsions are obtainable by mixing at least two immiscible liquids to which solid particles or grains are added.
When two immiscible liquids are brought together, an inter-phase area will be formed. By stirring the liquids, droplets are created increasing the inter-phase surface area. This is however an energetically unfavourable situation and the two phases will separate again when mixing is stopped. The droplets however can be partially or fully stabilized in the continuous phase by solid particles located at this inter-phase. Pickering first studied the principle of this stabilization method and reported this in 1907 (Pickering, S. U., Emulsions. J. Chem Soc. (London), 1907. 91: p. 2001-2021). In literature they are therefore often referred to as Pickering emulsions. The solid particles locate themselves at the inter-phase because of the difference in surface tension of the two liquids. Once located at this inter- phase the particle will remain there in a stable state. If enough particles are present, a hexagonal close packing (HCP) of solid particles can be achieved at the inter-phase. In this way, emulsion droplets can be stabilized with solid particles located at the inter-phase as shown in Fig. 17. The amount and the size of the globules can be controlled by the amount of solid material added or the volume of emulsified liquid. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Several documents are cited throughout the text of this specification. Each of the documents herein (including any manufacturer's specifications, instructions etc.) are hereby incorporated by reference; however, there is no admission that any document cited is indeed prior art of the present invention.
Table 1: Experimental data
Average and standard deviation measured for 4 a and 3 D experiments.
Table 2. Summary of the used suspension compositions, deposition parameters and results. All AC-EPD experiments and density measurements were repeated 3 times.
Control experiment performed using an absolute ethanol (Prolabo) based suspension and DC source. For this experiment a voltage of 200V was applied.
Claims
1. A coating process comprising the steps of: immersing an electrode or porous substrate placed in front of an electrode in an aqueous medium comprising charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles and subjecting said charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles in an aqueous medium to (asymmetric) unbalanced alternating current (UAC) electric fields, having a frequency and a positive and negative part each having an amplitude and a duration, to deposit electrophoretically said charged, partially charged or self-charging organic or metallo-organic molecules or colloidal particles onto said electrode or porous substrate placed in front of an electrode, characterised in that said amplitude of said unbalanced alternating current (UAC) electric field differs significantly for the positive and negative part, while maintaining a net integral of the applied signal over one period, i.e. average potential, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero. .
2. The coating process of claim 1, wherein said duration of the negative and positive part of said UAC electric fields differ in addition to said amplitude of the negative and positive part of said UAC electric fields while the overall integral over one period, i.e. average potential, is lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero.
3. The coating process of claim 1 or 2, whereby said charged or self-charging compounds or organic or metallo-organic molecules are dissolved in said aqueous medium.
4. The coating process of claim 1 or 2, whereby the charged or self-charging compounds or organic or metallo-organic molecules are incorporated in colloidal particles in suspension in the aqueous medium or in an aqueous slurry.
5. The coating process of claim 1 or 2, whereby the charged or self-charging compounds or organic or metallo-organic molecules are incorporated in charged or self-charging solid particles that stabilize an emulsion.
6. The coating process of any one of claims 1 to 5, whereby the charged or self-charging compounds or organic or metallo-organic molecules are in or from living or killed cells, cell organelles or cell components.
7. The coating process of any one of claims 1 to 5, whereby the charged compounds or organic or metallo-organic molecules are amino acids, nucleic acid molecules (e.g., RNA, DNA, oligonucleotides, polynucleotides, mixed polymers, peptide nucleic acid, and the like), peptides (e.g., polyaminoacids, polypeptides, proteins and the like).
8. The coating process of any one of claims 1 to 5, whereby the charged or self-charging compounds or organic or metallo-organic molecules are macromolecules.
9. The coating process of any one of claims 1 to 5, whereby the charged or self-charging compounds or organic or metallo-organic molecules are a bio-active agent.
10. Use of the coating process of any one of claims 1 to 9 to form smooth deposits with no visible defects having a surface with a Ra of 10 to 50 μm, preferably a Ra of 10 to 10000 nm, more preferably a Ra of 10 to 500 nm, and most preferably a Ra of 10 -200 nm..
11. The use according to claim 10 to form a deposit with green density > 30 %.
12. The use according to claim 10 or 11 to form a deposit with green density > 50 %.
13. The use according to claim 10 or 11 to form a deposit with green density > 60 %.
14. The use according to any one of claims 10 to 13 to produce a device or instrument.
15. The use according to any one of claims 10 to 13 to coat or paint a device or instrument.
16. The use according to any one of claims 10 to 13 to immobilise charged or self-charging compounds or organic or metallo-organic molecules from an aqueous medium in a patterned structure on a substrate.
17. The use according to any one of claims 10 to 13 to produce a medical prosthesis, an orthopaedic implant, dental endodontic or dental implant.
18. The use according to any one of claims 10 to 13 to coat a medical prosthesis, an orthopaedic implant, dental endodontic or dental implant.
19. The use according to any one of claims 10 to 13 to produce strong lightweight metals or alloys.
20. The use according to any one of claims 10 to 13 to produce a food or feed.
21. The use according to any one of claims 10 to 13 to produce a biocompatible implant.
22. The use according to any one of claims 10 to 13 to form a deposit with an average thickness in the nm size range.
23) The use according to any one of claims 10 to 13 to form a deposit with an average thickness in the micrometer scale.
24. The use according to any one of claims 10 to 13 to form a deposit with an average thickness in the millimeter scale.
25. The use according to any one of claims 10 to 13 to form a deposit with an average thickness in the centimeter scale.
26. The use according to any one of claims 10 to 13 to coat components of a bioreactor.
27. The use according to any one of claims 10 to 13 to produce monolithic objects, hollow objects, thin wall objects, membranes or wire for instance nanowires.
28. The use according to any one of claims 10 to 13 to produce anionic monolithic, hollow, wired or film objects.
29. The use according to any one of claims 10 to 13 to produce cationic monolithic, hollow, wired or film objects.
30. The use according to any one of claims 10 to 13 to produce films of cationic polymers.
31. The use according to any one of claims 10 to 13 to produce films of anionic polymers.
32. The use according to any one of claims 10 to 13 to coat an implant, in particular an arterial or venal implant by a coating or layer with a compound selected from the group of consistence of polytetrafluoroethylene, polyethylene, polypropylene, polybutene, polyurethane, polyvinylpyrrolidone, polyethylene oxide, hyaluronic acid polymers, mixtures thereof and copolymers thereof.
33. The use according to any one of claims 10 to 13 to coat a conductive substrate with organics such as monomers, precursors, hydrocarbons, functional hydrocarbons, macromolecules, oligosaccharides, polysaccharides, polymers (e.g. thermoplastic polymers, thermo curing polymers, biopolymers, alginates, carrageen or other algae derived polymers, kollicoat IR, or resins, oligomers some of which can be bioactive and others biocompatible.
34. A system for electrocoating a conductive substrate with organic or metallo-organic molecules or particles in which said system coats said conductive substrate with at least one layer or coating at a controllable average thickness in the nm, the μm, the mm or in the cm scale from a suspension in an aqueous working medium of one or more types of said organic or metallo-organic molecules or particles, wherein said system comprises a power supply connected to a signal generator to generate between a counter electrode and said conductive substrate, an unbalanced alternating current (UAC) signal, said signal having a frequency and a positive and negative part each having an amplitude and a duration, in which said amplitudes for said positive and negative parts differ significantly, while maintaining a net integral of the applied voltage over one period, i.e. average potential, lower in absolute value than 4V, preferably lower than 1.24V and most preferably equal to zero, and furthermore said system comprises a control system connected to said signal generator for determining the frequency and amplitude of said unbalanced AC signal.
35. The system for electrocoating of claim 34, whereby said frequency is at least 5Hz.
36. The system for electrocoating of claim 34, whereby said signal generator in operation generates an unbalanced alternating current (UAC) signal with a frequency in the range between 1 Hz and 1 kHz
37. The system for electrocoating of claim 34, whereby said signal generator in operation generates an unbalanced alternating current (UAC) signal with a frequency in the range between 10 Hz and 200 Hz
38. The system for electrocoating of claim 34, whereby said signal generator in operation generates an unbalanced alternating current (UAC) signal with a frequency in the range between 15 Hz and 100 Hz
39) The system for electrocoating of claim 34, whereby said frequency of said unbalanced signal (UAC) has an applied signal strength between 1 V peak to peak and 10000 V peak to peak
40. The system for electrocoating of claim 34, whereby said frequency of said unbalanced signal (UAC) has an applied signal strength between 10 V peak to peak and 5000V peak to peak
41. The system for electrocoating of claim 34, whereby said frequency of said unbalanced signal (UAC) has an applied signal strength between 50 V peak to peak and 1000 V peak to peak.
42. The system for electrocoating of claim 34, whereby said unbalanced signal or UAC over the interelectrode distance between said counter electrode and said conductive substrate provides an electric field strength between 100 V/m and 106 V/m
43. The system for electrocoating of claim 34, whereby said unbalanced signal or UAC over the interelectrode distance between said counter electrode and said conductive substrate provides an electric field strength between 1000 V/m and 105 V/m
44. The system for electrocoating of claim 34, whereby said unbalanced signal or UAC over the interelectrode distance between said counter electrode and said conductive substrate provides an electric field strength between 2500 V/m and 25000 V/m.
45. The system for electrocoating of claim 34, wherein said amplitude is 10 to 5000 volts peak to peak (Vp-p).
46. The system for electrocoating of claim 34, said amplitude is 25 to 2500 volts peak to peak (Vp-p).
47. The system for electrocoating of claim 34, said amplitude is 50 to 1000 volts peak to peak (Vp-p).
48. The system for electrocoating of claim 34, whereby said signal generator in operation generates an unbalanced alternating current (AC) signal with a frequency in the range between 15 Hz and 100 Hz and with an amplitude of 50 to 1000 volts peak to peak (Vp-
P)-
49. The system for electrocoating of claim 34, with an amplitude of 500 volts peak to peak (Vp-p), a frequency of 1 to 50 Hz and an asymmetry factor of 4.
50. The system of any one of claims 34 to 49, whereby said signal generator is an auxiliary electrode that if powered by the power supply under control of the control system generates the unbalanced electrical potential without electrolysing the aqueous working solution between the conductive substrate and said the auxiliary electrode.
51. The system of claim 50, whereby said control system comprises a function generator and an amplifier (amp).
52. The system of claim 43, whereby said control system comprises an oscilloscope (O- scope).
53. The system of any one of claims 34 to 52, whereby said system further comprises a sensor system for transmitting information regarding said electrophoretic deposition response to said unbalanced alternating current in said electrophoretic deposition aqueous medium and a pump system acting in response to said information communicated to said pump system to deliver a responsive dose of charged or self- charging organic or metallo-organic molecules or a responsive dose of an appropriate conductivity regulating agent in said electrophoretic deposition aqueous medium .
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19431608P | 2008-09-26 | 2008-09-26 | |
US19539208P | 2008-10-06 | 2008-10-06 | |
GBGB0818403.8A GB0818403D0 (en) | 2008-10-08 | 2008-10-08 | Aqueous electrophoretic deposition |
PCT/EP2009/062472 WO2010034826A2 (en) | 2008-09-26 | 2009-09-25 | Aqueous electrophoretic deposition |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2331731A2 true EP2331731A2 (en) | 2011-06-15 |
Family
ID=40042457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09736877A Withdrawn EP2331731A2 (en) | 2008-09-26 | 2009-09-25 | Aqueous electrophoretic deposition |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110168558A1 (en) |
EP (1) | EP2331731A2 (en) |
GB (1) | GB0818403D0 (en) |
WO (1) | WO2010034826A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9453289B2 (en) * | 2010-04-13 | 2016-09-27 | Lawrence Livermore National Security, Llc | Methods of three-dimensional electrophoretic deposition for ceramic and cermet applications and systems thereof |
CN103053060B (en) | 2010-08-05 | 2016-02-24 | 和光纯药工业株式会社 | Non-aqueous electrolyte and the non-aqueous electrolyte cell using it |
US9190695B2 (en) * | 2010-08-05 | 2015-11-17 | Wako Pure Chemical Industries, Ltd. | Nonaqueous electrolyte solution, method for producing same, and nonaqueous electrolyte battery using the electrolyte solution |
EP2685974A2 (en) | 2011-03-18 | 2014-01-22 | Katholieke Universiteit Leuven KU Leuven Research & Development | Inhibition and treatment of biofilms |
EP2739719A2 (en) * | 2011-08-02 | 2014-06-11 | Tokyo Electron Limited | System and method for tissue construction using an electric field applicator |
US9835926B2 (en) | 2012-03-21 | 2017-12-05 | E Ink California, Llc | Electrophoretic dispersion |
US10288975B2 (en) | 2012-03-21 | 2019-05-14 | E Ink California, Llc | Electrophoretic dispersion including charged pigment particles, uncharged additive nanoparticles, and uncharged neutral density particles |
WO2013142554A1 (en) * | 2012-03-21 | 2013-09-26 | Sipix Imaging, Inc. | Electrophoretic dispersion |
KR102137754B1 (en) * | 2012-08-31 | 2020-07-24 | 신에쓰 가가꾸 고교 가부시끼가이샤 | Production method for rare earth permanent magnet |
US10138564B2 (en) | 2012-08-31 | 2018-11-27 | Shin-Etsu Chemical Co., Ltd. | Production method for rare earth permanent magnet |
JP6107546B2 (en) * | 2012-08-31 | 2017-04-05 | 信越化学工業株式会社 | Rare earth permanent magnet manufacturing method |
WO2014112726A1 (en) * | 2013-01-15 | 2014-07-24 | 서강대학교산학협력단 | Electro-osmotic pump using reversible electrode reaction and fluid pumping system using same |
WO2015030466A1 (en) * | 2013-08-26 | 2015-03-05 | 서강대학교산학협력단 | Electroosmotic pump and fluid pumping system having same |
US10376841B2 (en) * | 2013-08-26 | 2019-08-13 | Sogang University Research & Business Development Foundation | Electroosmotic pump and fluid pumping system including the same |
JP6191497B2 (en) | 2014-02-19 | 2017-09-06 | 信越化学工業株式会社 | Electrodeposition apparatus and method for producing rare earth permanent magnet |
JP6090589B2 (en) | 2014-02-19 | 2017-03-08 | 信越化学工業株式会社 | Rare earth permanent magnet manufacturing method |
WO2017165407A1 (en) * | 2016-03-22 | 2017-09-28 | The Trustees Of Princeton University | Electrohydrodynamically formed structures of carbonaceous material |
KR102006908B1 (en) * | 2016-06-28 | 2019-08-02 | 이오플로우(주) | Electroosmotic pump and system for pumping of fluid comprising thereof |
US10413913B2 (en) | 2017-02-15 | 2019-09-17 | Tokyo Electron Limited | Methods and systems for dielectrophoresis (DEP) separation |
JP7113024B2 (en) * | 2017-03-28 | 2022-08-04 | マックス-プランク-ゲゼルシャフト ツール フェルデルング デア ヴィッセンシャフテン エー. ファオ. | Method and apparatus for creating three-dimensional bodies, in particular green bodies |
GB201808106D0 (en) * | 2018-05-18 | 2018-07-04 | Cambridge Entpr Ltd | Collagen biomaterials and methods for manufacturing collagen biomaterials |
JP7348454B2 (en) | 2018-10-01 | 2023-09-21 | 東京エレクトロン株式会社 | Apparatus and method for electrostatically removing foreign matter from a substrate surface |
TWI695910B (en) * | 2018-10-31 | 2020-06-11 | 國立清華大學 | Radiatively cooling substrate and manufacturing method thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1589327A (en) * | 1925-04-07 | 1926-06-15 | Eastman Kodak Co | Electrodeposition of coatings of cellulosic compounds |
US1583704A (en) * | 1925-06-08 | 1926-05-04 | Eastman Kodak Co | Electrodeposition of rubber under gas-removing conditions |
US2606147A (en) * | 1944-09-27 | 1952-08-05 | Poor & Co | Electrodeposition of arsenic |
BE640626A (en) * | 1961-08-23 | |||
GB1086325A (en) * | 1963-07-26 | 1967-10-11 | Goodlass Wall & Co Ltd | Process of electrophoretic deposition by means of alternating current |
CH482840A (en) * | 1966-03-03 | 1969-12-15 | Maeder Lack & Farben | Process for the electrophoretic deposition of coatings from a bath |
JPS5117968B2 (en) * | 1971-09-14 | 1976-06-07 | ||
US3959088A (en) * | 1975-03-19 | 1976-05-25 | The United States Of America As Represented By The Secretary Of The Army | Method and apparatus for generating high amperage pulses from an A-C power source |
JPS5569298A (en) * | 1978-11-17 | 1980-05-24 | Kureha Chem Ind Co Ltd | Electrodeposition method of protein |
DD215338A1 (en) * | 1983-06-03 | 1984-11-07 | Thuringia Sonneberg Veb | PROCESS FOR ELECTROPHORETIC SEPARATION OF DISPERSED PARTICLES |
US5126024A (en) * | 1989-12-19 | 1992-06-30 | Colorado School Of Mines | Apparatus and method for concentrating microorganisms from a liquid medium on an electrode by electrodeposition |
US5166063A (en) * | 1990-06-29 | 1992-11-24 | Eli Lilly And Company | Immobolization of biomolecules by enhanced electrophoretic precipitation |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
DE4440337A1 (en) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate |
US5503723A (en) * | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
PL192560B1 (en) * | 1996-08-22 | 2006-11-30 | Res Triangle Pharm Ltd | Composition containing microparticles of water-insoluble substances and method of obtaining such compositions |
US5855753A (en) * | 1996-11-26 | 1999-01-05 | The Trustees Of Princeton University | Method for electrohydrodynamically assembling patterned colloidal structures |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US5872443A (en) * | 1997-02-18 | 1999-02-16 | Williamson; Floyd L. | Electronic method for controlling charged particles to obtain optimum electrokinetic behavior |
KR19990001564A (en) * | 1997-06-16 | 1999-01-15 | 유충식 | Azole antifungal agents with improved solubility and preparations containing them |
US6241863B1 (en) * | 1998-04-27 | 2001-06-05 | Harold G. Monbouquette | Amperometric biosensors based on redox enzymes |
ES2251985T3 (en) * | 1999-03-24 | 2006-05-16 | R.P. Scherer Technologies, Inc. | GRANULATED PARTICLE TO IMPROVE THE WATER SOLUBILITY OF PHARMACOS, AND ITS PREPARATION PROCEDURE. |
US6814845B2 (en) * | 2001-11-21 | 2004-11-09 | University Of Kansas | Method for depositing an enzyme on an electrically conductive substrate |
US6879143B2 (en) * | 2002-04-16 | 2005-04-12 | Motorola, Inc. | Method of selectively aligning and positioning nanometer-scale components using AC fields |
GB0319797D0 (en) * | 2003-08-26 | 2003-09-24 | Leuven K U Res & Dev | Particle size reduction of poorly soluble drugs |
US7314542B2 (en) * | 2004-09-23 | 2008-01-01 | Nanogen, Inc. | Methods and materials for optimization of electronic transportation and hybridization reactions |
US20080142366A1 (en) * | 2006-12-13 | 2008-06-19 | Prabhakar Apparao Tamirisa | Incorporation of biomolecules in thin films |
-
2008
- 2008-10-08 GB GBGB0818403.8A patent/GB0818403D0/en not_active Ceased
-
2009
- 2009-09-25 EP EP09736877A patent/EP2331731A2/en not_active Withdrawn
- 2009-09-25 US US13/121,096 patent/US20110168558A1/en not_active Abandoned
- 2009-09-25 WO PCT/EP2009/062472 patent/WO2010034826A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2010034826A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010034826A3 (en) | 2010-09-10 |
GB0818403D0 (en) | 2008-11-12 |
WO2010034826A2 (en) | 2010-04-01 |
US20110168558A1 (en) | 2011-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110168558A1 (en) | Aqueous electrophoretic deposition | |
US8187500B2 (en) | Biphasic inks | |
Wei et al. | 2D particles at fluid–fluid interfaces: assembly and templating of hybrid structures for advanced applications | |
Fang et al. | Effect of molecular weight and pH on the self-assembly microstructural and emulsification of amphiphilic sodium alginate colloid particles | |
Lan et al. | Synergistic effect of silica nanoparticle and cetyltrimethyl ammonium bromide on the stabilization of O/W emulsions | |
Suh et al. | Natural nanocontainer for the controlled delivery of glycerol as a moisturizing agent | |
Servant et al. | Design, engineering and structural integrity of electro-responsive carbon nanotube-based hydrogels for pulsatile drug release | |
Chandran et al. | An electric field responsive drug delivery system based on chitosan–gold nanocomposites for site specific and controlled delivery of 5-fluorouracil | |
Wang et al. | Preparation, characterization and applications of low-molecular-weight alginate–oligochitosan nanocapsules | |
Lin et al. | Hollow mesoporous polydopamine nanospheres: synthesis, biocompatibility and drug delivery | |
EP2217295A1 (en) | Biodegradable colloidal gels as moldable tissue engineering scaffolds | |
Wang et al. | Fabrication of mesoporous silica nanoparticle with well-defined multicompartment structure as efficient drug carrier for cancer therapy in vitro and in vivo | |
Tang et al. | The microstructure and physiochemical stability of Pickering emulsions stabilized by chitosan particles coating with sodium alginate: Influence of the ratio between chitosan and sodium alginate | |
KR102079096B1 (en) | Method for producing porous calcium phosphate body, and porous calcium phosphate body produced thereby | |
CN102219938A (en) | Preparation method of hydrophobically modified sodium alginate | |
WO2019054948A1 (en) | Emulsions, methods and uses thereof | |
Udoetok et al. | Stabilization of pickering emulsions by iron oxide nano-particles | |
Muth et al. | Microstructure and elastic properties of colloidal gel foams | |
JP2015530393A5 (en) | ||
JP2009057627A (en) | Thick nanocolloidal gold liquid, fine gold particle, and their manufacturing methods | |
Wang et al. | Cationic surfactant-modified palygorskite particles as effective stabilizer for Pickering emulsion gel formation | |
Nair et al. | Poly (lactide-co-glycolide)–laponite–F68 nanocomposite vesicles through a single-step double-emulsion method for the controlled release of doxorubicin | |
Spyropoulos et al. | Fabrication and utilization of bifunctional protein/polysaccharide coprecipitates for the independent codelivery of two model actives from simple oil-in-water emulsions | |
Lengert et al. | Novel type of hollow hydrogel microspheres with magnetite and silver nanoparticles | |
Mallakpour et al. | Potential of tragacanth gum in the industries: a short journey from past to the future |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110329 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150401 |